OXIESEC PANEL
- Current Dir:
/
/
var
/
www
/
cream
/
assets
/
php
/
simplepie
/
library
/
SimplePie
/
Cache
Server IP: 139.59.38.164
Upload:
Create Dir:
Name
Size
Modified
Perms
π
..
-
05/19/2025 10:07:15 AM
rwxr-xr-x
π
00075c93132acf7a6e46e48d2291ce41.spc
5.69 KB
03/06/2025 09:42:25 AM
rw-r--r--
π
0102169e52b6a27a410e7b237202fe84.spc
140.81 KB
03/06/2025 09:42:25 AM
rw-r--r--
π
027d4dde1e82475da3d9afe4844afb1d.spc
2.63 KB
03/06/2025 09:42:25 AM
rw-r--r--
π
03036edfece701eaa1537fea4014dd44.spc
56.35 KB
03/06/2025 09:42:25 AM
rw-r--r--
π
0446f65691fba260d3eabbd1377240f8.spc
5.75 KB
03/06/2025 09:42:25 AM
rw-r--r--
π
04d0c6cc2bf146b1318b78f84416b912.spc
124.45 KB
03/06/2025 09:42:25 AM
rw-r--r--
π
0582678c8cfff117f770f9368b70c2b5.spc
19.33 KB
03/06/2025 09:42:25 AM
rw-r--r--
π
0601d608f5e2ea8e198130b17fe6ef01.spc
157 bytes
03/06/2025 09:42:25 AM
rw-r--r--
π
061ad7f2b0116c570fdc35c36824c7c6.spc
42.24 KB
03/06/2025 09:42:25 AM
rw-r--r--
π
06e0c598a46c483b6b9d775e1ba1ecd4.spc
124.09 KB
03/06/2025 09:42:25 AM
rw-r--r--
π
0802b12194f292de0e9d9617ac014785.spc
290.02 KB
03/06/2025 09:42:25 AM
rw-r--r--
π
083aed319a0b5c8691e31d9150d8005e.spc
19.84 KB
03/06/2025 09:42:25 AM
rw-r--r--
π
0a3bf48c84477cd58dbc2036a0331134.spc
70.63 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
0b5e5f226006af7e46d02ba8ce216a45.spc
54.71 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
0b73d04c6bba0acaf2f9a569f388313a.spc
33.59 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
0b8a46fca237497cfc90498f9eb909ab.spc
686.66 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
0ce2bdd7061489c6136e7614d421b874.spc
47.7 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
0de8a2204854bb5dd311607494c671e4.spc
828.58 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
0e15494dca4aeb24ea769582482c5162.spc
150.58 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
0eaec40cfb584fcb55fcdfb5d76684b9.spc
16.95 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
0ed254d4d9db6e3afe193b00bc6471bb.spc
89.85 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
0f079d9bb09fef940c38ee73b52b91d4.spc
34.42 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
0f5e21d9d8354d10ea23d99101259ba2.spc
42.06 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
0ffc1fa29a6bad7fb49e55940c374610.spc
75.61 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
1071b4a15b6c2fe6f7a96f194d0ba524.spc
196 bytes
03/06/2025 09:42:26 AM
rw-r--r--
π
10ae571a6266a8e21b0fbb15f552a1cb.spc
13.15 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
118c129ff99a905e4e9325e388b841fe.spc
45.34 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
131a4ad07dda46888cbbc1cb4c710a91.spc
59.6 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
132dee0a955be7733cc009e546de18da.spc
100.76 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
142d8795402a4e8a520be8ebea6f54f3.spc
22.7 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
1469d584e9747d132077c9df3cda6c97.spc
121.15 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
1479626ef8ef423638ca62f43b3e0f8d.spc
95.45 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
16e016e3ca27d793aa9172c1913c3f23.spc
26.74 KB
03/06/2025 09:42:26 AM
rw-r--r--
π
19f3a21c36072f501f634db8e658bc9f.spc
16.6 KB
03/06/2025 09:42:27 AM
rw-r--r--
π
1b8954ae7aab6fd9784cbcc827133f80.spc
186 bytes
03/06/2025 09:42:27 AM
rw-r--r--
π
1c0bbac8beea30e555f26fd02994e7a5.spc
19.96 KB
03/06/2025 09:42:27 AM
rw-r--r--
π
1c1a63fc25720b7c22c9c28fa2aa9379.spc
236.54 KB
03/06/2025 09:42:27 AM
rw-r--r--
π
1f1672e0ecc5e7a6d278c930015520ab.spc
166 bytes
03/06/2025 09:42:27 AM
rw-r--r--
π
1f4cf3ae9ba91935f556711c1cfc34d4.spc
88.33 KB
03/06/2025 09:42:27 AM
rw-r--r--
π
1f5e96e3f1a01f95ab611ec1458fe470.spc
169.16 KB
03/06/2025 09:42:27 AM
rw-r--r--
π
20a75b688975a2d5d342eae9f4c33411.spc
1.22 MB
03/06/2025 09:42:27 AM
rw-r--r--
π
225d97aca36305a8b407ea6d8d5b187e.spc
55.08 KB
03/06/2025 09:42:27 AM
rw-r--r--
π
242d3dabf79d13154fcc384ff8b2d25e.spc
113.19 KB
03/06/2025 09:42:27 AM
rw-r--r--
π
25512b0d18ae6e4d20d027abbc467365.spc
31.2 KB
03/06/2025 09:42:27 AM
rw-r--r--
π
25948504a82cd8da1985fddd4500c1c7.spc
153.7 KB
03/06/2025 09:42:27 AM
rw-r--r--
π
26e0c631724f3653c10c3123546ab5e2.spc
110.09 KB
03/06/2025 09:42:28 AM
rw-r--r--
π
2704664dff0e40e19de087fe00892bc2.spc
24.51 KB
03/06/2025 09:42:28 AM
rw-r--r--
π
274ae07ff50cfde2bda57a71703b62f4.spc
2.54 KB
03/06/2025 09:42:28 AM
rw-r--r--
π
2799184659106c88b5072a3e3f763a4d.spc
2.54 KB
03/06/2025 09:42:28 AM
rw-r--r--
π
2801f3bdd649962fa663f608c2383280.spc
154.53 KB
03/06/2025 09:42:28 AM
rw-r--r--
π
28099e26c5c9a06acb85a41ccd789efc.spc
500.36 KB
03/06/2025 09:42:28 AM
rw-r--r--
π
2aabe0323264e3f60916621039be0e76.spc
42.37 KB
03/06/2025 09:42:29 AM
rw-r--r--
π
2abcd685295b4a261ad2e866188e5e11.spc
125.3 KB
03/06/2025 09:42:29 AM
rw-r--r--
π
2aed529f6407470bef913050a1d118ef.spc
151 bytes
03/06/2025 09:42:29 AM
rw-r--r--
π
2b2654a64e8b0f5d9cf497e0883b2042.spc
96.1 KB
03/06/2025 09:42:29 AM
rw-r--r--
π
2dae1abba28ecd05f3e1e91f308cf8c4.spc
87.25 KB
03/06/2025 09:42:29 AM
rw-r--r--
π
2db16a36af8daf383cb739dd57a44d90.spc
147.19 KB
03/06/2025 09:42:29 AM
rw-r--r--
π
2de250597c053bd81359233c14c51db4.spc
286.38 KB
03/06/2025 09:42:29 AM
rw-r--r--
π
2fb670ecdcda7db936aa7d2f018a79e4.spc
23.75 KB
03/06/2025 09:42:29 AM
rw-r--r--
π
30d5af6cd4c10ea02520bcaba31f3d1c.spc
141.02 KB
03/06/2025 09:42:29 AM
rw-r--r--
π
31591159e55bceb27be71ce43cd1517e.spc
443.64 KB
03/06/2025 09:42:29 AM
rw-r--r--
π
31f817c15425941589a9819216265501.spc
68.33 KB
03/06/2025 09:42:30 AM
rw-r--r--
π
34661b0e5b23f423b303c946172b39f8.spc
20.99 KB
03/06/2025 09:42:29 AM
rw-r--r--
π
3567037b5acd1842946ba40397edead4.spc
84.5 KB
03/06/2025 09:42:30 AM
rw-r--r--
π
37cf2adae9335c54f1dbc436922e6cfc.spc
181 bytes
03/06/2025 09:42:30 AM
rw-r--r--
π
389ae768f4ecb350b56b92da3b04c1ac.spc
180.5 KB
03/06/2025 09:42:30 AM
rw-r--r--
π
3bcfb7838de30c68c7acc437c16935cc.spc
142.35 KB
03/06/2025 09:42:30 AM
rw-r--r--
π
3ca755a78dd04c91695e5fcee845991f.spc
42.02 KB
03/06/2025 09:42:31 AM
rw-r--r--
π
3d135369c757ae57c3c873e6070d5ac6.spc
46.18 KB
03/06/2025 09:42:31 AM
rw-r--r--
π
3e4e8d898fc42bca52bf888c3a33ef23.spc
614.85 KB
03/06/2025 09:42:33 AM
rw-r--r--
π
3e804b49f84699d48348b3bee312090d.spc
25.24 KB
03/06/2025 09:42:33 AM
rw-r--r--
π
3f92b590befbddc6f7237f2ff7a2ca21.spc
407.55 KB
03/06/2025 09:42:33 AM
rw-r--r--
π
3f93802ae5a285cffaf04f22ceb596fb.spc
307.02 KB
03/06/2025 09:42:33 AM
rw-r--r--
π
419e5468f73de12da7ac55b064ff6e04.spc
19.87 KB
03/06/2025 09:42:33 AM
rw-r--r--
π
43cdef0c688f38c395285fd09bd1d8b6.spc
163 bytes
03/06/2025 09:42:33 AM
rw-r--r--
π
445a8424173fb9de0f08493a09557c92.spc
39.14 KB
03/06/2025 09:42:33 AM
rw-r--r--
π
447b88825763019604aca4e363415120.spc
3.18 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
44a6e222af7ac1e000190688f3824d27.spc
103.66 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
45ec354e05ea3a553e89c9f9d1ee7a6f.spc
67.86 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
48926180fcc9ab4ab897cfbc5279409e.spc
170 bytes
03/06/2025 09:42:34 AM
rw-r--r--
π
4904c558085c30a9ca52969c7f875cf8.spc
155 bytes
03/06/2025 09:42:34 AM
rw-r--r--
π
490fd4abfc32189cff5d5f38ddaaff5b.spc
22.31 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
491e4a0adc576f7c32fdb7ee38bb0997.spc
88.77 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
492e918dde587df3095914b1f67cd6ee.spc
31.56 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
4b6d0ec22ab2dc33cffefef17cf9a288.spc
87.42 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
4b6fa8105439c52ea4f2c1f18e0957e2.spc
181 bytes
03/06/2025 09:42:34 AM
rw-r--r--
π
4c3facd12e8f40cab8114677f681ebaf.spc
134 bytes
03/06/2025 09:42:34 AM
rw-r--r--
π
4ca537d8aa4727a23841361c475118e1.spc
42.22 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
4d1bb795413f82f68c666caa0c0c27bb.spc
148.14 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
4e8baeaef3679f9460ffdecddbb1f6a7.spc
35.08 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
5064bfc366d30fb3250bafeacadc83db.spc
22.11 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
50ba71d2f35fb5e96b224d907d33d263.spc
720.35 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
51447ae67b6d856982df0ea0496cf24b.spc
18.89 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
522fe4b133aa24cb42c79b24ecb5c838.spc
134.37 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
5432740bf8126b80fd18515165c5cf20.spc
22.07 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
55fad6ae8bfedfb81fafc8bd5112a79f.spc
31.16 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
577d0589862161e3aaa25ed8758b2765.spc
29.23 KB
03/06/2025 09:42:34 AM
rw-r--r--
π
57e4b3f5cadf2d33fa630cb96499349a.spc
154 bytes
03/06/2025 09:42:35 AM
rw-r--r--
π
588359e68ff59d4ef53aaf3edb6a44cf.spc
6.77 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
5a06bba505584742f9e590f2f81e0ff3.spc
128 bytes
03/06/2025 09:42:35 AM
rw-r--r--
π
5c6d487a1fbb288f7f0f73b55f6b2df1.spc
41.86 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
5c744a4198beb7326dcf101f961486b4.spc
56.94 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
5ef8b2cef4776b3e3f9f79092ce932ca.spc
124.66 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
5fc9bcdda34ec7e72510b177a0164b7b.spc
602.71 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
60bc545cda9dafe75484b88be1dd4ae9.spc
67.49 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
60fe2edd86b212feb0f71552066ef55d.spc
186.19 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
6270f865db79068a5dedb78ba877e7a0.spc
100.02 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
6370a4a7eb9be29e32a96811bc0dd7b6.spc
19.59 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
63f55618eba7b0585577fb08ea8818dc.spc
41.42 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
651d4f6bf953adef7c5b8f05f01e1151.spc
32.47 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
66267a4d6dba7887fc7d4a1aa2da9b75.spc
123.73 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
663e01e065755a523f15f61782ef2fd0.spc
28.3 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
66506bf5272cefcb56085b4b77463bd8.spc
280.88 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
669fa07a0da20a5d0da35d972d5fcac5.spc
99.77 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
679d4423c6016aeb24557d767a509bbb.spc
46.29 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
69185497e5f13fd4744a2c39d76fb812.spc
32.55 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
69b3abe3aa88d144d3591d56873de72b.spc
150 bytes
03/06/2025 09:42:35 AM
rw-r--r--
π
6a0ab3ec7216c8caa50e266f3ff16993.spc
22.35 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
6c7544e2246a222bbde6ad7d0406c8db.spc
200.49 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
6c7c31384f1626a700bc8fbd2f584add.spc
57.94 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
6cf9d92f08956fa74016014a99dc793e.spc
28.51 KB
03/06/2025 09:42:35 AM
rw-r--r--
π
6ee565104f90a8212dd7e14133d6e4ae.spc
193 bytes
03/06/2025 09:42:35 AM
rw-r--r--
π
6eede30400457c4277e91f133b7a27a6.spc
60.73 KB
03/06/2025 09:42:36 AM
rw-r--r--
π
71f0008f42879a3e550851568b3494d0.spc
1.8 MB
03/06/2025 09:42:36 AM
rw-r--r--
π
72ff111641b87f5d234c3ded91959234.spc
136.69 KB
03/06/2025 09:42:36 AM
rw-r--r--
π
7400954e05f62bf45dcf5c1087223df4.spc
2.63 KB
03/06/2025 09:42:36 AM
rw-r--r--
π
7463e454c4ab831179d37c4e86643dc2.spc
266.75 KB
03/06/2025 09:42:36 AM
rw-r--r--
π
74a014a9f44690e4a045b1753c1ef5c9.spc
159 bytes
03/06/2025 09:42:36 AM
rw-r--r--
π
76c5af11f8b8bd34c58097da8689d2a2.spc
185.34 KB
03/06/2025 09:42:36 AM
rw-r--r--
π
76e6555adc909bfac627ceaba91df128.spc
167.17 KB
03/06/2025 09:42:36 AM
rw-r--r--
π
7ab2d04babf16e9d06f787e38f186748.spc
89.36 KB
03/06/2025 09:42:36 AM
rw-r--r--
π
7b9723cc6339397505e29dbe8497b10a.spc
150 bytes
03/06/2025 09:42:36 AM
rw-r--r--
π
7beeb799568e0584e407e788f7ec973d.spc
56.61 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
7c6fcaa553a1353d8fcc5535064f4008.spc
50.63 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
7d1ab5c52f2c3ab33c409e73bedecc5e.spc
3.92 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
7dc75885832733a5ea185d98887b82df.spc
33.47 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
7e7185a8ee7828937f2a05f0aa956f10.spc
162 bytes
03/06/2025 09:42:37 AM
rw-r--r--
π
80d5eace46cca553f0c7e7a631ed6703.spc
123.39 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
828f89042b67ae6fca8657110997c302.spc
3.94 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
8341235cab83dcb126f0ad2b5812b63d.spc
88.67 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
8353d08af859970965abdbc71f5bf9a3.spc
37.15 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
83efe9d0463ea50fa82517c4a92ed589.spc
158 bytes
03/06/2025 09:42:37 AM
rw-r--r--
π
8409cc881139fa5d466af5d757f19609.spc
48.09 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
84ed1e5a5cc7fb7930a3132f1dd7ae0a.spc
112.98 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
850a6a7f962502618892db457e231fe7.spc
131.61 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
852c8f9b4effcea04904f4e1e55da3f4.spc
459.08 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
874091b93fb13db66a5fdbe72fbb8d6b.spc
1.59 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
8b768f4e406ced9a4cba62897a7bc651.spc
97.91 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
8bbfe139e67e5f738b9ffcb18a7c5b86.spc
47.7 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
8d0823d0a4bd13241dc275b14e801667.spc
183.86 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
8d3db038a087fbdc54054a9282afa2c6.spc
164 bytes
03/06/2025 09:42:37 AM
rw-r--r--
π
8d64115de2ca5294e771c8614663c953.spc
162 bytes
03/06/2025 09:42:37 AM
rw-r--r--
π
8e24588eb23460ceefe5195686c2a6db.spc
101.38 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
906b5d59de170e528244744b925a8af5.spc
97.16 KB
03/06/2025 09:42:37 AM
rw-r--r--
π
91e1e8b556ae254fb44c93230478d3bb.spc
1.78 MB
03/06/2025 09:42:38 AM
rw-r--r--
π
925665a1ef421d5783a6690aaf7df881.spc
88.91 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
92c4233c5ea49b0f47ba9af6486e17f6.spc
64.88 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
949df90c5a085c17de656881d6a5dc97.spc
65.9 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
94b8ccc457e138e62b74ac96766909fe.spc
43.53 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
9670648a5cd87103a2bc6c99e516dbd7.spc
254.78 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
96c4f97f5353d399aeef3f49fcc0bd5a.spc
57.63 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
992f7d4247b62b8e56c4a6445f64e04b.spc
144 bytes
03/06/2025 09:42:38 AM
rw-r--r--
π
995cd56c60511ced48b0bb42e95ccb29.spc
85.8 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
99e1eb580536f979670980ef56caa779.spc
576.91 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
9af8106d738badb69af8dbe24a679341.spc
4.85 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
9b6240eda91c41ff776a575879c7a726.spc
54.8 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
9c32f356173958a68d3962b6f17561eb.spc
160 bytes
03/06/2025 09:42:38 AM
rw-r--r--
π
9e292139809beeb488509c95614d3e76.spc
1.56 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
9fe45b1c96a67767d7c125aa8c27bebc.spc
2.54 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
Base.php
3.35 KB
05/19/2025 10:07:15 AM
rw-r--r--
π
DB.php
4.6 KB
05/19/2025 10:07:15 AM
rw-r--r--
π
File.php
4.19 KB
05/19/2025 10:07:15 AM
rw-r--r--
π
Memcache.php
4.81 KB
05/19/2025 10:07:15 AM
rw-r--r--
π
Memcached.php
5.27 KB
05/19/2025 10:07:15 AM
rw-r--r--
π
MySQL.php
12.67 KB
05/19/2025 10:07:15 AM
rw-r--r--
π
Redis.php
3.77 KB
05/19/2025 10:07:15 AM
rw-r--r--
π
a0dd9524b935d91f0d0e610c7b9a1f95.spc
54.13 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
a0e811e382668a9493c9f9bcf755902f.spc
25.24 KB
03/06/2025 09:42:38 AM
rw-r--r--
π
a11bb1233ce40192adba9cdb21a3613c.spc
132 bytes
03/06/2025 09:42:38 AM
rw-r--r--
π
a12b910472ebb7b3a0c246d82cdec324.spc
165.79 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
a1306c489bd935407a80c0245167bb84.spc
428.11 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
a1e50aef8a606be18418a7d94b3bb8d2.spc
122.33 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
a2535462ba909c959bb0869d70ff56e8.spc
29.87 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
a314938317436bd1ebd038a1398b974f.spc
19.1 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
a40a776457ebfa5dcaef5c99f859250c.spc
133.2 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
a4ed082fee0233bdebb15a8f4a504fa6.spc
175.47 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
a576de3f9423beb68b07b459f555f5d8.spc
76.09 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
a8125aa761f75b13ea12ad2d89fbc3a6.spc
58.37 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
a889c422e716ac96d46950fb9c5ba801.spc
106.51 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
a989cfbb4ebcd4ea5aede2f8d18f6b80.spc
214.7 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
abfe9571c106187db93288b1ea97357a.spc
19.09 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
ac085086dda45b4acb5220884d7b42fb.spc
39.58 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
ad31539954a7a910a7ef71c0cff11e32.spc
651.17 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
adb7ca764a42bad01a0ccae2df09c2fa.spc
34.44 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
af4b85b1ea956523b25a690c1c87ed85.spc
7.54 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
b1ef373fca862552cd559336e342ca8d.spc
60.91 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
b1fc76c9199e2130438d81b6297c73fa.spc
123.07 KB
03/06/2025 09:42:39 AM
rw-r--r--
π
b44b9e448df189cee8d7c7774273267b.spc
66.4 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
b5b9fb6ba1e724416126f7788d4bd8b7.spc
19.16 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
b8e453c2d1e800f71ad2abe6f7862197.spc
199 bytes
03/06/2025 09:42:40 AM
rw-r--r--
π
b98b28ea3fd7b9216203c2195410da13.spc
185.21 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
bad310e570d6910886344039e409a70b.spc
58.37 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
bb3a0b2406a3458f919871c9bfac24d7.spc
78.58 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
bbb4e4b91e967dfb9857f287804d6854.spc
78.58 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
bc49456c91a82629235dab13b79d530c.spc
5.71 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
bd3c5c1472767419fe12061049343483.spc
122.03 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
beb279d0ed1b28135d1331bbeb778b85.spc
68.25 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
befdda147f5b773407a123a1eb9e1481.spc
20.58 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
c0c166f9ee4c843629b5b2b20a0a2086.spc
74.38 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
c168527cd70d44755d5e3dc302cff303.spc
96.85 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
c31156c2178130a5e98ebbb8b2f61319.spc
92.65 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
c330aaa4bb416ffe76b92bd7fa4a582a.spc
3.16 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
c3466198bca97aa364f02a5602bef651.spc
50.51 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
c37dda73a1483bdf0e7772e1e65479f1.spc
102.33 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
c49105af5fef08449f157af0549bf58b.spc
64.7 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
c5bf94a976a06fd3da7d2939ef9b2e93.spc
480.81 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
c5e0e65569698bc9792cddb93cca6c68.spc
118.78 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
c96754afef1f81a69a0494827bfa975c.spc
87.07 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
ca38db44e86990dad0ffc27892af2d69.spc
423.78 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
cb969645802f54c40492251f3bd3818b.spc
7.06 KB
03/06/2025 09:42:40 AM
rw-r--r--
π
cbd50ddc468d429034821a3a21440e73.spc
57.07 KB
03/06/2025 09:42:41 AM
rw-r--r--
π
cc3a8bf1cc63f8051fe7e45b14fca9fc.spc
61.94 KB
03/06/2025 09:42:41 AM
rw-r--r--
π
ce8b24d13ad5a0054d9ae1efeee95609.spc
57.6 KB
03/06/2025 09:42:41 AM
rw-r--r--
π
ce9a2f38c75aba09c31a410d4b086b2f.spc
28.28 KB
03/06/2025 09:42:41 AM
rw-r--r--
π
cec2dda9e5518b2ca7efedcdddb289f2.spc
1.5 MB
03/06/2025 09:42:41 AM
rw-r--r--
π
ced71a24d29f4c3018999b8ea94761ab.spc
35.85 KB
03/06/2025 09:42:41 AM
rw-r--r--
π
d018492df7f0a66d8411103e06d305fa.spc
2.9 MB
03/06/2025 09:42:42 AM
rw-r--r--
π
d266cfac3257b22a998f2f5b1bf8ac31.spc
35.77 KB
03/06/2025 09:42:41 AM
rw-r--r--
π
d59464babf88adbd572cbf3240ae91da.spc
2.55 KB
03/06/2025 09:42:42 AM
rw-r--r--
π
d63686ffe3376b92d8b4ba02a520a2bd.spc
40.59 KB
03/06/2025 09:42:42 AM
rw-r--r--
π
d6c6d1245a9ca93671ff33ef06329534.spc
41.3 KB
03/06/2025 09:42:43 AM
rw-r--r--
π
d816bb54778bcf17ba8ed16089bfa393.spc
47.04 KB
03/06/2025 09:42:43 AM
rw-r--r--
π
d8c5aac1146a5e6b3c91488029d275be.spc
18.96 KB
03/06/2025 09:42:43 AM
rw-r--r--
π
d8eefb559112e58cb4dab21367a186e2.spc
341.6 KB
03/06/2025 09:42:43 AM
rw-r--r--
π
d9db250644ba2877f115f509ace5a7b5.spc
19.27 KB
03/06/2025 09:42:43 AM
rw-r--r--
π
da5b74a1b7ac788a6c7db30034f9f799.spc
76.51 KB
03/06/2025 09:42:43 AM
rw-r--r--
π
da7dd3f84bdafec1857c9c04b9b53f49.spc
117.83 KB
03/06/2025 09:42:43 AM
rw-r--r--
π
daadcfa75586a3a6698743b245181714.spc
20.01 KB
03/06/2025 09:42:43 AM
rw-r--r--
π
dad664e4362c3317a36adbd6bfa95d4c.spc
58.98 KB
03/06/2025 09:42:44 AM
rw-r--r--
π
db6a0a5cfed88c8c6db5be3169997c27.spc
38.74 KB
03/06/2025 09:42:44 AM
rw-r--r--
π
dbc9e5458fbfe789c8bd64599935a222.spc
161 bytes
03/06/2025 09:42:44 AM
rw-r--r--
π
dc3bbfb8c5e33be6aec482a3a6c003cd.spc
260.91 KB
03/06/2025 09:42:44 AM
rw-r--r--
π
dc689c7a8814cebe543897aa3a044b9e.spc
136 bytes
03/06/2025 09:42:44 AM
rw-r--r--
π
dc7b0425002a35c26a812e42646cc5af.spc
110.95 KB
03/06/2025 09:42:44 AM
rw-r--r--
π
df45183a85d0f0324d9f35c8c667f311.spc
123.39 KB
03/06/2025 09:42:44 AM
rw-r--r--
π
e1d26f40ba214b9e9d94a92389e4d5d8.spc
130.79 KB
03/06/2025 09:42:44 AM
rw-r--r--
π
e1ec95a656a063e573f412b2c7488133.spc
98.16 KB
03/06/2025 09:42:44 AM
rw-r--r--
π
e2fe7980a50e21a17e83fde0f82077c6.spc
159 bytes
03/06/2025 09:42:44 AM
rw-r--r--
π
e33522c8d17d816500b215c32a7b5849.spc
424.31 KB
03/06/2025 09:42:44 AM
rw-r--r--
π
e398f7edc1ab874296c6c9fed54e4399.spc
57.99 KB
03/06/2025 09:42:44 AM
rw-r--r--
π
e6748eb4f66ad85c15d3973ba8d274b3.spc
16.19 KB
03/06/2025 09:42:44 AM
rw-r--r--
π
ea703f3e5c39f76615e5a8b975f794a2.spc
18.93 KB
03/06/2025 09:42:44 AM
rw-r--r--
π
ee4eec2e7e2d0266fa0e6eb5a151c7e9.spc
56.4 KB
03/06/2025 09:42:44 AM
rw-r--r--
π
ee5afdacabc2bf5b99888e862c58b0cb.spc
187 bytes
03/06/2025 09:42:44 AM
rw-r--r--
π
eedc719891428769b3318fba58ebe6c8.spc
91.81 KB
03/06/2025 09:42:45 AM
rw-r--r--
π
f3fc3643d931e468c7037823a54cc6c2.spc
3.97 MB
03/06/2025 09:42:45 AM
rw-r--r--
π
f4114707b5c9cf5d98010c3a1f8b38ec.spc
141 bytes
03/06/2025 09:42:45 AM
rw-r--r--
π
f52ed8c534a9a161e74c7b34e79c9f24.spc
60.07 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
f6bf66d8f1b939c68d68e9ae777c9ee1.spc
99.38 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
f718d57993920295b2d6ec7c8028db7b.spc
69.33 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
f72d38fe0ddd5db20158445a4e897562.spc
127 bytes
03/06/2025 09:42:46 AM
rw-r--r--
π
f74498a86970a084e5ca639447042aa3.spc
89.37 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
f781c182570da74dd9393a580af5d0b5.spc
110.45 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
f7d657440800849c7fcaeb682984c7e6.spc
87.15 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
f81cbff939f27fcdc536cbf121abb8ad.spc
120.51 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
f84cd96c8a71b247154b19e30d315391.spc
24.9 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
f8a0bf8a6e507649e6924b7906ba448b.spc
16.56 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
f9cf779dc17343f7a142ab34fefeb6eb.spc
622.21 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
fa736b27a4ac645b8161f4a084aa97f7.spc
58.64 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
faff66c685366de77bd8b616b29f384f.spc
64.5 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
fbbc76af945486db16d13c379b759bde.spc
1.24 MB
03/06/2025 09:42:46 AM
rw-r--r--
π
fbc57cfd03bf1e4ef525660536f2fc4c.spc
19.03 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
fcde86f9229908845a8ebdc70d387d67.spc
65.27 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
fd653df8381ec085d867b89d482aed73.spc
66.47 KB
03/06/2025 09:42:46 AM
rw-r--r--
π
fd99424fd37ab7b5b16649d14b1f1d93.spc
90.79 KB
03/06/2025 09:42:47 AM
rw-r--r--
π
fec16c4cebc5c84650054735667e7319.spc
34.25 KB
03/06/2025 09:42:47 AM
rw-r--r--
Editing: 6c7544e2246a222bbde6ad7d0406c8db.spc
Close
a:4:{s:5:"child";a:1:{s:0:"";a:1:{s:3:"rss";a:1:{i:0;a:6:{s:4:"data";s:4:" ";s:7:"attribs";a:1:{s:0:"";a:1:{s:7:"version";s:3:"2.0";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:1:{s:7:"channel";a:1:{i:0;a:6:{s:4:"data";s:288:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:8:{s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:30:"RETINA - Most Popular Articles";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:76:"https://journals.lww.com/retinajournal/pages/viewallmostpopulararticles.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:148:"RETINA provides current information on diagnostic and therapeutic techniques in vitreoretinal disorders. Subscribe to this must have journal today! ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"language";a:1:{i:0;a:5:{s:4:"data";s:5:"en-us";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:13:"lastBuildDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Fri, 17 May 2024 05:12:28 -0500";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"generator";a:1:{i:0;a:5:{s:4:"data";s:35:"Wolters Kluwer Health RSS Generator";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"image";a:1:{i:0;a:6:{s:4:"data";s:26:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:3:{s:3:"url";a:1:{i:0;a:5:{s:4:"data";s:90:"https://images.journals.lww.com/retinajournal/XLargeThumb.00006982-202405000-00000.CV.jpeg";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:30:"RETINA - Most Popular Articles";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:76:"https://journals.lww.com/retinajournal/pages/viewallmostpopulararticles.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}}s:4:"item";a:50:{i:0;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:110:"https://journals.lww.com/retinajournal/fulltext/2024/03000/lightsite_iii__13_month_efficacy_and_safety.14.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:277:"Boyer, David; Hu, Allen; Warrow, David; Xavier, Samantha; Gonzalez, Victor; Lad, Eleonora; Rosen, Richard B.; Do, Diana; Schneiderman, Todd; Ho, Allen; Munk, Marion R.; Jaffe, Glenn; Tedford, Stephanie E.; Croissant, Cindy L.; Walker, Michael; RΓΌckert, Rene; Tedford, Clark E.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:196:"LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1683:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/03000/lightsite_iii__13_month_efficacy_and_safety.14.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202403000-00014.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: The LIGHTSITE III study evaluated multiwavelength photobiomodulation (PBM) therapy in nonexudative (dry) age-related macular degeneration (AMD) using the LumiThera Valeda Light Delivery System. Methods: LIGHTSITE III is a randomized, controlled trial to assess the safety and effectiveness of PBM in dry AMD. Subjects were given multiwavelength PBM (590, 660, and 850 nm) or Sham treatment delivered in a series of nine sessions over 3 to 5 weeks every four months over 24 months. Subjects were assessed for efficacy and safety outcomes. Data from the 13-month analysis are presented in this report. Results: A total of 100 subjects (148 eyes) with dry AMD were randomized. LIGHTSITE III met the primary efficacy best-corrected visual acuity endpoint with a significant difference between PBM (n = 91 eyes) and Sham (n = 54 eyes) groups (Between group difference: 2.4 letters (SE 1.15), CI: β4.7 to β0.1, P = 0.02) (PBM alone: 5.4 letters (SE 0.96), CI: 3.5 to 7.3, P < 0.0001; Sham alone: 3.0 letters (SE 1.13), CI: 0.7β5.2, P < 0.0001). The PBM group showed a significant decrease in new onset geographic atrophy (P = 0.024, Fisher exact test, odds ratio 9.4). A favorable safety profile was observed. Conclusion: LIGHTSITE III provides a prospective, randomized, controlled trial showing improved clinical and anatomical outcomes in intermediate dry AMD following PBM therapy.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Fri, 01 Mar 2024 00:00:00 GMT-06:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:68:"RETINA. 44(3):487-497, March 2024. doi: 10.1097/IAE.0000000000003980";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202403000-00014";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:1;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:110:"https://journals.lww.com/retinajournal/fulltext/2024/03000/retinal_optical_coherence_tomography_imaging.1.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:72:"Pandya, Bhadra U.; Grinton, Michael; Mandelcorn, Efrem D.; Felfeli, Tina";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:6:"Review";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:83:"RETINAL OPTICAL COHERENCE TOMOGRAPHY IMAGING BIOMARKERS: A Review of the Literature";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2379:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/03000/retinal_optical_coherence_tomography_imaging.1.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202403000-00001.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: The aim of this literature review was to summarize novel optical coherence tomography (OCT) imaging biomarkers that have recently been described in the literature and are frequently encountered clinically. Methods: The literature was reviewed to identify novel OCT biomarkers reported to date. A descriptive summary of all terms and representative illustrations were provided to highlight the most relevant features. Results: Thirty-seven OCT terminologies were identified. The vitreomacular interface disorder group included the four stages of epiretinal membrane, macular pseudohole, tractional lamellar hole (LH), degenerative LH, cotton ball sign, and foveal crack sign. The age-related macular degeneration group included outer retinal tubulation, multilayered pigment epithelial detachment, prechoroidal cleft, onion sign, double-layer sign, complete outer retinal atrophy, complete retinal pigment epithelium and outer retinal atrophy, and reticular pseudodrusen. The uveitic disorder group consisted of bacillary layer detachment, syphilis placoid, rain-cloud sign, and pitchfork sign. The disorders relating to the toxicity group included flying saucer sign and mitogen-activated protein kinase (MEK) inhibitorβassociated retinopathy. The disorders associated with the systemic condition group included choroidal nodules and needle sign. The pachychoroid spectrum group included pachychoroid and brush border pattern. The vascular disorder group included pearl necklace sign, diffuse retinal thickening, disorganization of retinal inner layers, inner nuclear layer microcysts, hyperreflective retinal spots, paracentral acute middle maculopathy, and acute macular neuroretinopathy. The miscellaneous group included omega sign (Ο), macular telangiectasia (type 2), and omega sign (Ξ©). Conclusions: Thirty-seven OCT terminologies were summarized, and detailed illustrations consolidating the features of each biomarker were included. A nuanced understanding of OCT biomarkers and their clinical significance is essential because of their predictive and prognostic value.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Fri, 01 Mar 2024 00:00:00 GMT-06:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:68:"RETINA. 44(3):369-380, March 2024. doi: 10.1097/IAE.0000000000003974";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202403000-00001";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:2;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:112:"https://journals.lww.com/retinajournal/fulltext/2023/11000/comparison_of_three_internal_limiting_membrane.6.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:125:"Feng, Jingyang; Shao, Qing; Xie, Jiaming; Yu, Jiayi; Li, Menghan; Liu, Chen; Zhou, Siheng; Zhou, Hao; Wang, Weijun; Fan, Ying";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:154:"COMPARISON OF THREE INTERNAL LIMITING MEMBRANE PEELING TECHNIQUES FOR MYOPIC TRACTION MACULOPATHY WITH HIGH RISK OF POSTOPERATIVE MACULAR HOLE DEVELOPMENT";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2095:"<a href="https://journals.lww.com/retinajournal/fulltext/2023/11000/comparison_of_three_internal_limiting_membrane.6.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202311000-00006.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To compare three different internal limiting membrane (ILM) peeling techniques, including standard ILM peeling, fovea-sparing ILM peeling, and inverted ILM flap (ILMF), in the treatment of myopic traction maculopathy with high risk of postoperative macular hole development. Method: This retrospective cohort study enrolled 101 eyes suffering from lamellar macular hole combined with myopic traction maculopathy in 98 consecutive patients who underwent vitrectomy with either standard ILM peeling, fovea-sparing ILM peeling, or ILMF from July 2017 to August 2020. All patients were followed up for at least 12 months after surgery. Best-corrected visual acuity, macular anatomical outcomes, and postoperative full-thickness macular hole (FTMH) formation were evaluated. Results: No significant differences were found among the three surgical groups in baseline characteristics. 12 months after surgery, the mean best-corrected visual acuity was significantly improved (P < 0.001) and showed no significant differences among groups (P = 0.452). None of the eyes in the ILMF group, five eyes (15.6%) in the standard ILM peeling group, and six eyes (17.1%) in the fovea-sparing ILM peeling group developed a postoperative FTMH (P = 0.026). Logistic regression showed that the ILM peeling technique was an independent influencing factor for FTMH formation (OR = 0.209, P = 0.014). Conclusion: Compared with the standard ILM peeling or fovea-sparing ILM peeling technique, the ILMF technique resulted in similar visual outcomes but a relatively low incidence of postoperative FTMH in the treatment of lamellar macular hole combined with myopic traction maculopathy. Inverted ILM flap is an effective technique for treating myopic traction maculopathy with high risk of postoperative FTMH development.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Thu, 19 Oct 2023 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:74:"RETINA. 43(11):1872-1880, November 2023. doi: 10.1097/IAE.0000000000003882";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202311000-00006";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:3;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:112:"https://journals.lww.com/retinajournal/fulltext/2024/05000/dexamethasone_implant_versus_topical_carbonic.13.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:171:"Colombo, Leonardo; Montesano, Giovanni; Di Domenico, Alice; Colizzi, Benedetta; Rissotto, Roberta; Maltese, Paolo; Bertelli, Matteo; Autelitano, Alessandro; Rossetti, Luca";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:185:"DEXAMETHASONE IMPLANT VERSUS TOPICAL CARBONIC ANHYDRASE INHIBITORS IN PATIENTS WITH BILATERAL RETINITIS PIGMENTOSAβRELATED CYSTOID MACULAR EDEMA: A Prospective, Paired-Eye Pilot Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2072:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/05000/dexamethasone_implant_versus_topical_carbonic.13.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202405000-00013.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To compare within-subject efficacy and safety of intravitreal dexamethasone implant and topical carbonic anhydrase inhibitors in the treatment of retinitis pigmentosaβrelated cystoid macular edema. Methods: Patients with bilateral retinitis pigmentosaβrelated cystoid macular edema were treated with intravitreal dexamethasone implant in one eye and topical carbonic anhydrase inhibitors in the contralateral eye. The primary endpoint was a change in central macular thickness. Secondary endpoints were changes in best-corrected visual acuity and microperimetric central retinal sensitivity. Intraocular pressure and other ocular complications were evaluated for safety assessment. Results: Nine patients were recruited for this 12-month follow-up study. Central macular thickness was significantly lower in intravitreal dexamethasone implantβtreated eyes than in topical carbonic anhydrase inhibitorsβtreated eyes at Months 1 and 7, whereas mean best-corrected visual acuity was better in eyes treated with topical carbonic anhydrase inhibitors at Month 12 (borderline significant P = 0.0510). There was no difference in microperimetric sensitivity between the two treatments. Three patients developed ocular hypertension after intravitreal dexamethasone implant. Intravitreal dexamethasone implant showed an effect on the contralateral eye in five of nine patients. Conclusion: Intravitreal dexamethasone implant was more effective than topical carbonic anhydrase inhibitors in reducing retinitis pigmentosaβrelated cystoid macular edema 1 month after treatment. Corticosteroids can play a key role in the management of retinitis pigmentosaβrelated cystoid macular edema; however, their routes, timing, and modes of administration should be further explored.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Thu, 18 Apr 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 44(5):852-860, May 2024. doi: 10.1097/IAE.0000000000004039";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202405000-00013";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:4;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:115:"https://journals.lww.com/retinajournal/fulltext/2024/05000/the_effect_of_internal_limiting_membrane_peeling.10.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:76:"Belkin, Avner; Harel, Gal; Shtayer, Chen; Bercovich, Or; Rubowitz, Alexander";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:125:"THE EFFECT OF INTERNAL LIMITING MEMBRANE PEELING ON THE INNER RETINAL LAYERS IN PATIENTS WITHOUT MACULAR PATHOLOGIC CONDITION";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2158:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/05000/the_effect_of_internal_limiting_membrane_peeling.10.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202405000-00010.F1.jpeg" border="0" align ="left" alt="image"/></a>Background: To examine the effect of internal limiting membrane peeling on the inner retinal layers in patients without macular pathological condition. Methods: A prospective nonrandomized trial of patients undergoing pars plana vitrectomy with internal limiting membrane peeling for pathologic condition outside the macula was performed. Optical coherence tomography including macular ganglion cell layer, inner plexiform layer, and peripapillary retinal nerve fiber layer imaging was performed before surgery, 1, 3, and 6 months postoperatively, and at the end of follow-up (ranges between 4 and 17 months). Patients with any macular pathological condition on optical coherence tomography before surgery were excluded. The main outcome measure was change in thickness of the ganglion cell layer and inner plexiform layer. Results: Ten patients who underwent pars plana vitrectomy with internal limiting membrane peeling for macula-on retinal detachment were included in the analysis. The mean age was 55 years, and the mean follow up was 10.8 months. All patients completed at least two postoperative follow-up visits that included an optical coherence tomography as per the protocol (range 2β6 months). There was an immediate reduction in the global (G), inferotemporal, superotemporal, and superior (S) ganglion cell layer thickness at the first follow up as compared with the preoperative state (P = 0.028, P = 0.027, P = 0.026, and P = 0.027 respectively). From the first follow-up visit onward until the final follow-up, the thinning persisted, although there was no further statistically significant thinning. Conclusion: Peeling of the internal limiting membrane causes significant ganglion cell layer thinning in maculae without pathologic condition before surgery. At up to 17 months of follow-up, this effect seems to be immediate and nonprogressive.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Thu, 18 Apr 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 44(5):831-836, May 2024. doi: 10.1097/IAE.0000000000004042";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202405000-00010";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:5;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:117:"https://journals.lww.com/retinajournal/fulltext/2024/05000/a_modified_suturing_technique_to_produce_temporary.23.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:15:"Zhang, Zhaotian";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:18:"Surgical Technique";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:123:"A Modified Suturing Technique to Produce Temporary Scleral Buckling Effect for Noncomplex Rhegmatogenous Retinal Detachment";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2204:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/05000/a_modified_suturing_technique_to_produce_temporary.23.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202405000-00023.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To introduce a surgical technique for temporary scleral buckling of noncomplex rhegmatogenous retinal detachment using a combination of nonabsorbable and absorbable sutures that would induce minimal permanent refractive changes. Methods: Twenty consecutive patients (20 eyes) with noncomplex rhegmatogenous retinal detachment were prospectively included. Scleral buckling was performed in all eligible subjects, and encircling buckling was added when necessary. The silicone elements were fixed on the sclera with 5-0 nonabsorbable sutures and tightened to form a ridge with 6-0 absorbable sutures. Best-corrected visual acuity, scleral ridge status, axial length, spherical diopter, and cylinder diopter were collected. Results: All patients achieved primary retinal reattachment with significant improvement of best-corrected visual acuity after surgery. Scleral ridge was obvious and in situ at the 1-month follow-up but diminished at the 3-month follow-up. At the 1-month follow-up, axial length increased from 24.78 mm Β± 2.14 mm preoperatively to 25.22 mm Β± 2.11 mm, and cylinder diopter increased from β1.99 Β± 1.03 to β2.95 Β± 1.55 (both P < 0.001). At the 3-month follow-up, axial length, spherical diopter, and cylinder diopter decreased significantly compared with the values at the 1-month follow-up (all P < 0.05). No obvious complications were observed during the whole follow-up. Patients who underwent additional encircling buckling exhibited greater changes in axial length and cylinder diopter at the 1-month follow-up (both P < 0.001). Conclusion: The modified technique of scleral buckling with/without encircling buckling using both nonabsorbable and absorbable sutures offers a safe and effective option to repair noncomplex rhegmatogenous retinal detachment, which would offer an adequate temporary scleral buckling effect and induce minimal permanent refractive changes.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Thu, 18 Apr 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 44(5):928-933, May 2024. doi: 10.1097/IAE.0000000000004031";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202405000-00023";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:6;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:112:"https://journals.lww.com/retinajournal/fulltext/2024/05000/guided_trocar_insertion_in_highly_myopic_eyes.22.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:119:"Savastano, Alfonso; Bernardinelli, Patrizio; De Vico, Umberto; Amorelli, Giulia Maria; Niutta, Matteo; Rizzo, Stanislao";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:18:"Surgical Technique";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:45:"Guided Trocar Insertion in Highly Myopic Eyes";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1984:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/05000/guided_trocar_insertion_in_highly_myopic_eyes.22.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202405000-00022.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To demonstrate through a diagnostic test used as a new preoperative assessment that trocar insertion for pars plana vitrectomy could be safely placed at a distance >4.0 mm in highly myopic eyes to facilitate the surgical maneuvers. Methods: Thirty eyes of 30 patients were tested with a biometer for the axial length measurement and with ultrasound biomicroscopy to measure the pars plana length. Pars plana lengths of highly myopic eyes were then compared with those of emmetropic eyes. The surgeon also measured the pars plana of highly myopic eyes intraoperatively and compared it with ultrasound measurements to assess ultrasound biomicroscopy reliability. Results: The mean axial length was 23.81 mm (SD Β± 0.30) in the control group and 31.11 mm (SD Β± 0.56) in the myopic group. The mean pars plana length was 4.96 mm (SD Β± 0.19) in control eyes and 6.65 (SD Β± 0.36) in myopic eyes. An extremely significant statistical difference (P < 0.001) was obtained by comparing the length of pars plana between control eyes and myopic eyes. The results of pars plana measurements were 6.65 mm (SD Β± 0.36, ultrasound biomicroscopy) and 6.66 mm (SD Β± 0.34, intraoperative measurements) in myopic eyes. The statistical comparison of the measurements in these two groups did not give a statistically significant result (P = 0.950). Conclusion: Ultrasound biomicroscopy is a reliable technique to calculate the length of pars plana in highly myopic eyes, where this parameter is significantly greater than that of emmetropic eyes. Trocars insertion for pars plana vitrectomy may be performed, in eyes with axial length >30 mm, in relative safety at a distance to limbus higher than 4 mm.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Thu, 18 Apr 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 44(5):923-927, May 2024. doi: 10.1097/IAE.0000000000003997";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202405000-00022";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:7;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:107:"https://journals.lww.com/retinajournal/fulltext/2024/04000/comparison_of_the_efficacy_and_safety_of.16.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:151:"Su, Tong; Lai, Dongwei; Wu, Yang; Gu, Chufeng; He, Shuai; Meng, Chunren; Cai, Chunyang; Zhang, Jingfa; Luo, Dawei; Chen, Jili; Zheng, Zhi; Qiu, Qinghua";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:187:"COMPARISON OF THE EFFICACY AND SAFETY OF RANIBIZUMAB 0.5 MG VERSUS 1.0 MG WITH PARS PLANA VITRECTOMY FOR THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY: A Randomized Controlled Trial";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2136:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/04000/comparison_of_the_efficacy_and_safety_of.16.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202404000-00016.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To investigate the effectiveness of two regimens of ranibizumab-assisted pars plana vitrectomy in the treatment of patients with proliferative diabetic retinopathy. Methods: This is a prospective, 6-month, randomized controlled trial. Eighty patients with 87 eyes requiring pars plana vitrectomy treatment for proliferative diabetic retinopathy were included and randomly divided into a 1.0-mg injection group and a 0.5-mg injection group. The ranibizumab was delivered intraoperatively, at the close of surgery. The vitreous hemorrhage grade, best-corrected visual acuity, central macular thickness, and safety data were assessed to Month 6. Results: The 1.0-mg injection group had a milder grade and a lower reoccurrence rate of early postoperatively vitreous hemorrhage than the 0.5-mg injection group (35.0% and 63.4%, respectively, P = 0.0195). The mean best-corrected visual acuity of two groups was significantly improved from baseline to 6 months after surgery, 1.60 Β± 0.72 Logarithm of the Minimum Angle of Resolution (LogMAR) (<20/200) to 0.47 Β± 0.49 LogMAR (20/59) for the 1.0-mg injection group and 1.51 Β± 0.69 LogMAR (<20/200) to 0.50 Β± 0.31 LogMAR (20/63) for the 0.5-mg injection group, but there was no significant difference between the two groups (P = 0.74). There was no significant difference in the mean decrease in central macular thickness and probability of postoperative adverse events between the two groups. Conclusion: Intravitreal injection of 1.0 mg of ranibizumab after pars plana vitrectomy compared with the recommended dose of 0.5 mg significantly reduced the recurrence and severity of early postoperative vitreous hemorrhage in patients with proliferative diabetic retinopathy. It also contributed to the early recovery of visual acuity after surgery and did not increase postoperative adverse events.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 01 Apr 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:68:"RETINA. 44(4):680-688, April 2024. doi: 10.1097/IAE.0000000000003998";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202404000-00016";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:8;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:115:"https://journals.lww.com/retinajournal/fulltext/2017/10000/systemic_pharmacokinetics_and_pharmacodynamics_of.6.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:239:"Avery, Robert L.; Castellarin, Alessandro A.; Steinle, Nathan C.; Dhoot, Dilsher S.; Pieramici, Dante J.; See, Robert; Couvillion, Stephen; Nasir, Ma'an A.; Rabena, Melvin D.; Maia, Mauricio; Van Everen, Sherri; Le, Kha; Hanley, William D.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:104:"SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1778:"<a href="https://journals.lww.com/retinajournal/fulltext/2017/10000/systemic_pharmacokinetics_and_pharmacodynamics_of.6.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-201710000-00006.T1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO). Methods: Prospective, open-label, nonrandomized clinical trial of patients with AMD, DME, or RVO who were antivascular endothelial growth factor (VEGF) naΓ―ve or had not received anti-VEGF for β₯4 months. Patients received 3 monthly intravitreal injections of aflibercept 2.0 mg, bevacizumab 1.25 mg, or ranibizumab (0.5 mg for AMD/RVO, 0.3 mg for DME). The main outcome measures were serum PKs and plasma free-VEGF concentrations after the first and third injections. Results: A total of 151 patients were included. In AMD/DME/RVO, systemic exposure to each drug was highest with bevacizumab, then aflibercept, and lowest with ranibizumab. Ranibizumab cleared from the bloodstream more quickly than bevacizumab or aflibercept. Aflibercept treatment resulted in the greatest reductions in plasma free-VEGF relative to baseline levels, whereas ranibizumab treatment resulted in the smallest decreases in plasma free-VEGF. Conclusion: The three anti-VEGF treatments examined in this analysis demonstrated notable differences in systemic PKs. Generally, the reduction in plasma free-VEGF levels correlated with elevated levels of circulating anti-VEGF agents, with the reduction in free-VEGF levels greatest with aflibercept and least with ranibizumab.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Sun, 01 Oct 2017 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:73:"RETINA. 37(10):1847-1858, October 2017. doi: 10.1097/IAE.0000000000001493";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-201710000-00006";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:9;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:116:"https://journals.lww.com/retinajournal/fulltext/2021/08000/retinal_fluid_and_thickness_as_measures_of_disease.1.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:116:"Kaiser, Peter K.; Wykoff, Charles C.; Singh, Rishi P.; Khanani, Arshad M.; Do, Diana V.; Patel, Hersh; Patel, Nikhil";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:6:"Review";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:107:"RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1834:"<a href="https://journals.lww.com/retinajournal/fulltext/2021/08000/retinal_fluid_and_thickness_as_measures_of_disease.1.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202108000-00001.T1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: Retinal fluid and thickness are important anatomical features of disease activity in neovascular age-related macular degeneration, as evidenced by clinical trials that have used these features for inclusion criteria, retreatment criteria, and outcome measures of the efficacy of intravitreal injections of antiβvascular endothelial growth factor agents. Methods: A literature review of anatomical measures of disease activity was conducted. Results: Treatment goals for neovascular age-related macular degeneration include improving/maintaining vision by drying the retina, and several analyses have evaluated the relationship between visual function and anatomy. The change in retinal thickness has been found to correlate with the change in the visual acuity, and variation in retinal thickness may predict visual acuity outcomes. In addition, specific fluid compartments may have different prognostic values. For example, the presence of intraretinal fluid has been associated with poorer visual acuity, whereas the presence of subretinal fluid has been associated with better visual acuity. Retinal fluid and thickness are important for selecting dosing interval durations in clinical trials and clinical practice. Conclusion: Retinal thickness and retinal fluid are common anatomical measures of disease activity in neovascular age-related macular degeneration. Further research is required to fully elucidate the relationship between anatomical features and visual outcomes in neovascular age-related macular degeneration.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Thu, 06 May 2021 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:71:"RETINA. 41(8):1579-1586, August 2021. doi: 10.1097/IAE.0000000000003194";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202108000-00001";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:10;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:114:"https://journals.lww.com/retinajournal/fulltext/2021/01000/the_angiopoietin_tie_pathway_in_retinal_vascular.1.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:197:"Heier, Jeffrey S.; Singh, Rishi P.; Wykoff, Charles C.; Csaky, Karl G.; Lai, Timothy Y.Y.; Loewenstein, Anat; Schlottmann, Patricio G.; Paris, Liliana P.; Westenskow, Peter D.; Quezada-Ruiz, Carlos";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:6:"Review";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:67:"THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES: A Review";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1831:"<a href="https://journals.lww.com/retinajournal/fulltext/2021/01000/the_angiopoietin_tie_pathway_in_retinal_vascular.1.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202101000-00001.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To provide a concise overview for ophthalmologists and practicing retina specialists of available clinical evidence of manipulating the angiopoietin/tyrosine kinase with immunoglobulin-like and endothelial growth factorβlike domains (Tie) pathway and its potential as a therapeutic target in retinal vascular diseases. Methods: A literature search for articles on the angiopoietin/Tie pathway and molecules targeting this pathway that have reached Phase 2 or 3 trials was undertaken on PubMed, Association for Research in Vision and Ophthalmology meeting abstracts (2014β2019), and ClinicalTrials.gov databases. Additional information on identified pipeline drugs was obtained from publicly available information on company websites. Results: The PubMed and Association for Research in Vision and Ophthalmology meeting abstract search yielded 462 results, of which 251 publications not relevant to the scope of the review were excluded. Of the 141 trials related to the angiopoietin/Tie pathway on ClinicalTrials.gov, seven trials focusing on diseases covered in this review were selected. Vision/anatomic outcomes from key clinical trials on molecules targeting the angiopoietin/Tie pathway in patients with retinal vascular diseases are discussed. Conclusion: Initial clinical evidence suggests a potential benefit of targeting the angiopoietin/Tie pathway and vascular endothelial growth factor-A over antiβvascular endothelial growth factor-A monotherapy alone, in part due to of the synergistic nature of the pathways.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Fri, 01 Jan 2021 00:00:00 GMT-06:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:67:"RETINA. 41(1):1-19, January 2021. doi: 10.1097/IAE.0000000000003003";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202101000-00001";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:11;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:107:"https://journals.lww.com/retinajournal/fulltext/2024/01000/a_systematic_literature_review_of_disease.1.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:94:"Lam, Byron L.; Scholl, Hendrik P. N.; Doub, Daneal; Sperling, Marvin; Hashim, Mahmoud; Li, Nan";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:6:"Review";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:111:"A SYSTEMATIC LITERATURE REVIEW OF DISEASE PROGRESSION REPORTED IN RPGR-ASSOCIATED X-LINKED RETINITIS PIGMENTOSA";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2014:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/01000/a_systematic_literature_review_of_disease.1.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202401000-00001.T1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: Retinitis pigmentosa GTPase regulatorβassociated X-linked retinitis pigmentosa (RPGR-associated XLRP) is a rare and severe form of retinitis pigmentosa, resulting in progressive visual impairment; however, disease progression data are limited. A systematic literature review was conducted to assess available data on disease progression in RPGR-associated XLRP. Methods: PubMed, Embase, and select congress abstracts were evaluated through June 2022. Eligible studies included results specific to RPGR-associated XLRP or populations with β₯80% of patients with retinitis pigmentosa carrying disease-causing RPGR variants. End points of interest included visual acuity, visual field, ellipsoid zone width, progression to blindness, and patient-reported outcomes. Results: Fourteen studies met β₯1 end point of interest. Progressive declines in visual acuity, visual field, and ellipsoid zone width were reported across studies. Nearly all publications reported annual declines in visual acuity (3.5%β8.2%). Annual visual field declines ranged from 4.2% to 13.3%. Changes in retinal structure were also observed (ellipsoid zone width changes: β177 to β830 Β΅m/year). Most studies measured blindness using visual acuity; visual fieldβbased definitions resulted in blindness by age βΌ25 years. Patient-reported outcome data were limited. Conclusion: Published evidence shows that patients with RPGR-associated XLRP experience progressive decline in visual acuity, visual field, and ellipsoid zone width, eventually resulting in blindness. Additional longitudinal data with standardized end points and expanded collection of patient-reported outcomes are needed to assess visual decline in RPGR-associated XLRP.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 01 Jan 2024 00:00:00 GMT-06:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 44(1):1-9, January 2024. doi: 10.1097/IAE.0000000000003920";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202401000-00001";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:12;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:109:"https://journals.lww.com/retinajournal/fulltext/2024/01000/pigment_epithelial_detachment_thickness_and.2.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:150:"Sarraf, David; Khanani, Arshad M.; Sadda, SriniVas R.; Chang, Andrew; Wong, David T.; Kempf, Anne-Sophie; Saffar, Insaf; Tang, Shuhan; Tadayoni, Ramin";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:141:"PIGMENT EPITHELIAL DETACHMENT THICKNESS AND VARIABILITY AFFECTS VISUAL OUTCOMES IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1691:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/01000/pigment_epithelial_detachment_thickness_and.2.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202401000-00002.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To evaluate the impact of pigment epithelial detachment (PED) thickness (i.e., height) and thickness variability on best-corrected visual acuity outcomes in patients with neovascular age-related macular degeneration in the Phase 3 HAWK and HARRIER trials. Methods: Optical coherence tomography images from the pooled brolucizumab 6 mg and aflibercept 2 mg arms were analyzed for the maximum PED thickness across the macula at baseline through to week 96. Best-corrected visual acuity outcomes were compared in patients with different PED thickness and variability cut-off thresholds. Results: Greater PED thickness at baseline or at week 12 was associated with lower mean best-corrected visual acuity gain from baseline to week 96 (baseline PED β₯200 Β΅m: +4.6 letters; <200 Β΅m: +7.0 letters; week 12 PED β₯100 Β΅m: +5.6 letters; <100 Β΅m: +6.6 letters). Eyes with the largest PED thickness variability from week 12 through week 96 gained fewer letters from baseline at week 96 (β₯33 Β΅m: +3.3 letters; <9 Β΅m: +6.2 letters). Furthermore, increased PED thickness at week 48 was associated with higher prevalence of intraretinal and subretinal fluid. Conclusion: In this treatment-agnostic analysis, greater PED thickness and PED thickness variability were associated with poorer visual outcomes in patients with neovascular age-related macular degeneration and greater neovascular activity.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 01 Jan 2024 00:00:00 GMT-06:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:68:"RETINA. 44(1):10-19, January 2024. doi: 10.1097/IAE.0000000000003935";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202401000-00002";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:13;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:107:"https://journals.lww.com/retinajournal/fulltext/2017/05000/the_pathophysiology_of_geographic_atrophy.2.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:109:"Boyer, David S.; Schmidt-Erfurth, Ursula; van Lookeren Campagne, Menno; Henry, Erin C.; Brittain, Christopher";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:6:"Review";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:138:"THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1777:"<a href="https://journals.lww.com/retinajournal/fulltext/2017/05000/the_pathophysiology_of_geographic_atrophy.2.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-201705000-00002.F1-2.jpeg" border="0" align ="left" alt="image"/></a>Purpose: Geographic atrophy (GA) is an advanced, vision-threatening form of age-related macular degeneration (AMD) affecting approximately five million individuals worldwide. To date, there are no approved therapeutics for GA treatment; however, several are in clinical trials. This review focuses on the pathophysiology of GA, particularly the role of complement cascade dysregulation and emerging therapies targeting the complement cascade. Methods: Primary literature search on PubMed for GA, complement cascade in age-related macular degeneration. ClinicalTrials.gov was searched for natural history studies in GA and clinical trials of drugs targeting the complement cascade for GA. Results: Cumulative damage to the retina by aging, environmental stress, and other factors triggers inflammation via multiple pathways, including the complement cascade. When regulatory components in these pathways are compromised, as with several GA-linked genetic risk factors in the complement cascade, chronic inflammation can ultimately lead to the retinal cell death characteristic of GA. Complement inhibition has been identified as a key candidate for therapeutic intervention, and drugs targeting the complement pathway are currently in clinical trials. Conclusion: The complement cascade is a strategic target for GA therapy. Further research, including on natural history and genetics, is crucial to expand the understanding of GA pathophysiology and identify effective therapeutic targets.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 01 May 2017 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 37(5):819-835, May 2017. doi: 10.1097/IAE.0000000000001392";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-201705000-00002";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:14;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:109:"https://journals.lww.com/retinajournal/fulltext/2024/05000/surgical_drainage_methods_during_pars_plana.1.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:120:"Grad, Justin R.; Hatamnejad, Amin; Huan, Peter W.; Popovic, Marko M.; McKay, Bryon R.; Kertes, Peter J.; Muni, Rajeev H.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:6:"Review";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:131:"SURGICAL DRAINAGE METHODS DURING PARS PLANA VITRECTOMY FOR RHEGMATOGENOUS RETINAL DETACHMENT: A Systematic Review and Meta-Analysis";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1801:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/05000/surgical_drainage_methods_during_pars_plana.1.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202405000-00001.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To assess efficacy and safety outcomes of subretinal fluid drainage methods during pars plana vitrectomy for rhegmatogenous retinal detachment. Methods: A systematic search strategy was conducted for studies published between January 2000 and October 2022. Included studies reported on either the safety or efficacy of two or more drainage methods during pars plana vitrectomy for patients with rhegmatogenous retinal detachment. Results: Two randomized and five observational studies consisting of 1,524 eyes were included. Best-corrected visual acuity at the last study observation and primary reattachment rates were similar across groups. A significantly lower risk of epiretinal membrane formation was associated with draining subretinal fluid through preexisting retinal breaks (risk ratio = 0.70, 95% confidence interval = [0.60, 0.83], P = <0.01, I2 = 0%) or with perfluorocarbon liquid (risk ratios = 0.70, 95% confidence interval = [0.59, 0.83], P = <0.01, I2 = 0%) compared with posterior retinotomy. The risk of an abnormal foveal contour was significantly greater in perfluorocarbon liquidβtreated eyes relative to posterior retinotomy (risk ratios = 1.56, 95% confidence interval = [1.13, 2.17], P = <0.01, I2 = 0%). Conclusion: No significant differences were observed in the final best-corrected visual acuity at the last study observation and primary reattachment rates across different drainage methods. There remains limited information on the topic, so future research is warranted.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Wed, 01 May 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 44(5):747-755, May 2024. doi: 10.1097/IAE.0000000000004083";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202405000-00001";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:15;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:113:"https://journals.lww.com/retinajournal/fulltext/2019/10000/choroidal_nevus_imaging_features_in_3,806_cases.2.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:205:"Shields, Carol L.; Dalvin, Lauren A.; Ancona-Lezama, David; Yu, Michael D.; Di Nicola, Maura; Williams, Basil K. Jr; Lucio-Alvarez, J. Antonio; Ang, Su Mae; Maloney, Sean; Welch, R. Joel; Shields, Jerry A.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:167:"CHOROIDAL NEVUS IMAGING FEATURES IN 3,806 CASES AND RISK FACTORS FOR TRANSFORMATION INTO MELANOMA IN 2,355 CASES: The 2020 Taylor R. Smith and Victor T. Curtin Lecture";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2963:"<a href="https://journals.lww.com/retinajournal/fulltext/2019/10000/choroidal_nevus_imaging_features_in_3,806_cases.2.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-201910000-00002.T1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To use multimodal imaging for identification of risk factors for choroidal nevus transformation into melanoma. Methods: Retrospective chart review of 3806 consecutive choroidal nevi with imaging and 2355 choroidal nevi with additional follow up to identify factors predictive of transformation of choroidal nevus into melanoma. Results: The median patient age was 62.5 years and Caucasian race in 3167 (95%). The choroidal nevus demonstrated median basal diameter of 4.0 mm and thickness of 1.4 mm. Imaging included optical coherence tomography (OCT) showing subretinal fluid (SRF) in 312 (9%), ultrasonography (US) with acoustic hollowness in 309 (9%), and hyper-autofluorescence (AF) in 100 (3%). Of those 2355 choroidal nevi with follow up, Kaplan-Meier estimates of nevus transformation into melanoma at 1, 5, and 10 years were 1.2%, 5.8%, and 13.9%, respectively. Multivariate analysis, using multimodal imaging for detection of factors predictive of nevus transformation into melanoma, included thickness >2 mm on US (hazard ratio (HR) 3.80, p < 0.0001), SRF on OCT as cap over nevus (HR 3.00, p < 0.0001) or SRF β€3 mm from nevus margin (HR 3.56, p = 0.0003), symptomatic vision loss β€20/50 on Snellen visual acuity (VA) (HR 2.28, p = 0.005), orange pigment (lipofuscin) hyperautofluorescence on AF (HR 3.07, p = 0.0004), acoustic hollowness on US (HR 2.10, p = 0.0020), and tumor diameter >5 mm on photography (HR 1.84, p = 0.0275). These factors can be recalled by the mnemonic βTo Find Small Ocular Melanoma Doing IMagingβ (TFSOM-DIM) representing Thickness >2 mm (US), Fluid subretinal (OCT), Symptoms vision loss (VA), Orange pigment (AF), Melanoma hollow (US), and DIaMeter >5mm (photography). The mean 5-year estimates of nevus growth into melanoma were 1% (HR 0.8) for those with 0 risk factor, 11% (HR 3.09) with 1 factor, 22% (HR 10.6) with 2 factors, 34% (HR 15.1) with 3 factors, 51% (HR 15.2) with 4 factors, 55% (HR 26.4) with 5 risk factors, and not-estimable with all 6 risk factors. Conclusion: In this analysis, multimodal imaging was capable of detecting risk factors for nevus transformation into melanoma, including thickness >2 mm (US), fluid subretinal (OCT), symptoms vision loss (Snellen acuity), orange pigment (AF), melanoma hollowness (US), and diameter >5 mm (photography). Increasing number of risk factors imparts greater risk for nevus transformation into melanoma, including thickness >2 mm (US), fluid subretinal (OCT), symptoms vision loss (Snellen acuity), orange pigment (AF), melanoma hollowness (US), and diameter >5 mm (photography). Increasing number of risk factors imparts greater risk for transformation.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Tue, 01 Oct 2019 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:73:"RETINA. 39(10):1840-1851, October 2019. doi: 10.1097/IAE.0000000000002440";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-201910000-00002";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:16;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:115:"https://journals.lww.com/retinajournal/fulltext/2024/04000/central_and_peripheral_involvement_of_the_retina.18.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:204:"Santos, Ana Rita; Almeida, Ana Catarina; Rocha, Ana ClΓ‘udia; Reste-Ferreira, DΓ©bora; Marques, InΓͺs Pereira; Cunha-Vaz Martinho, AntΓ³nio; Mendes, LuΓs; Santos, Torcato; Lewis, Warren; Cunha-Vaz, JosΓ©";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:94:"CENTRAL AND PERIPHERAL INVOLVEMENT OF THE RETINA IN THE INITIAL STAGES OF DIABETIC RETINOPATHY";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1676:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/04000/central_and_peripheral_involvement_of_the_retina.18.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202404000-00018.T1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To determine the degree of central microvascular closure using optical coherence tomography angiography in eyes of patients with type 2 diabetes with visible lesions only in the central retina or only in the periphery. Methods: Cross-sectional study. All 127 eyes underwent ultra-widefield fundus photography 200Β° examinations with OPTOS California (Optos, Dunfermline, United Kingdom) and Cirrus Angioplex optical coherence tomography angiography 3 Γ 3 mm acquisitions (ZEISS, Dublin, CA). Results: Twenty-five eyes showed visible lesions only in the central retina, 57 only in the peripheral retina, and 45 presented visible lesions in entire retina. The group with visible lesions only in the periphery showed definite closure in the superficial capillary plexus in 49% of the eyes, whereas the group with visible lesions only in the central seven-early treatment diabetic retinopathy study fields area showed a definite closure in 64%. Conclusion: Central capillary closure is already present in the initial stages of diabetic retinopathy even when lesions are only visible in the peripheral retina. Capillary closure in the superficial capillary plexus is three times more frequent than in the deep capillary plexus, demonstrating earlier closure of the superficial capillary plexus. Eyes with visible lesions only in the periphery show a milder form of retinopathy.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 01 Apr 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:68:"RETINA. 44(4):700-706, April 2024. doi: 10.1097/IAE.0000000000004021";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202404000-00018";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:17;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:111:"https://journals.lww.com/retinajournal/fulltext/2020/08000/a_double_masked,_randomized,_sham_controlled,.3.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:202:"Markowitz, Samuel N.; Devenyi, Robert G.; Munk, Marion R.; Croissant, Cindy L.; Tedford, Stephanie E.; RΓΌckert, Rene; Walker, Michael G.; Patino, Beatriz E.; Chen, Lina; Nido, Monica; Tedford, Clark E.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:147:"A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1967:"<a href="https://journals.lww.com/retinajournal/fulltext/2020/08000/a_double_masked,_randomized,_sham_controlled,.3.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202008000-00003.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: The LIGHTSITE I study investigated the efficacy and safety of photobiomodulation (PBM) treatment in subjects with dry age-related macular degeneration. Methods: Thirty subjects (46 eyes) were treated with the Valeda Light Delivery System, wherein subjects underwent two series of treatments (3Γ per week for 3β4 weeks) over 1 year. Outcome measures included best-corrected visual acuity, contrast sensitivity, microperimetry, central drusen volume and drusen thickness, and quality of life assessments. Results: Photobiomodulation-treated subjects showed a best-corrected visual acuity mean letter score gain of 4 letters immediately after each treatment series at Month 1 (M1) and Month 7 (M7). Approximately 50% of PBM-treated subjects showed improvement of β₯5 letters versus 13.6% in sham-treated subjects at M1. High responding subjects (β₯5-letter improvement) in the PBM-treated group showed a gain of 8 letters after initial treatment (P < 0.01) and exhibited earlier stages of age-related macular degeneration disease. Statistically significant improvements in contrast sensitivity, central drusen volume, central drusen thickness, and quality of life were observed (P < 0.05). No device-related adverse events were reported. Conclusion: Photobiomodulation treatment statistically improved clinical and anatomical outcomes with more robust benefits observed in subjects with earlier stages of dry age-related macular degeneration. Repeated PBM treatments are necessary to maintain benefits. These pilot findings support previous reports and suggest the utility of PBM as a safe and effective therapy in subjects with dry age-related macular degeneration.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Sat, 01 Aug 2020 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:71:"RETINA. 40(8):1471-1482, August 2020. doi: 10.1097/IAE.0000000000002632";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202008000-00003";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:18;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:108:"https://journals.lww.com/retinajournal/fulltext/2024/04000/incidence_and_risk_factors_of_intraocular.20.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:494:"Inoda, Satoru; Takahashi, Hidenori; Maruyama-Inoue, Maiko; Ikeda, Shoko; Sekiryu, Tetsuju; Itagaki, Kanako; Matsumoto, Hidetaka; Mukai, Ryo; Nagai, Yoshimi; Ohnaka, Masayuki; Kusuhara, Sentaro; Miki, Akiko; Okada, Annabelle A.; Nakayama, Makiko; Nishiguchi, Koji M.; Takeuchi, Jun; Mori, Ryusaburo; Tanaka, Koji; Honda, Shigeru; Kohno, Takeya; Koizumi, Hideki; Miyara, Yasunori; Inoue, Yuji; Takana, Hiroki; Iida, Tomohiro; Maruko, Ichiro; Hayashi, Atsushi; Ueda-Consolvo, Tomoko; Yanagi, Yasuo";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:146:"INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1760:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/04000/incidence_and_risk_factors_of_intraocular.20.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202404000-00020.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To investigate the incidence of intraocular inflammation (IOI) and its risk factors following intravitreal injections of brolucizumab for neovascular age-related macular degeneration in Japan. Methods: A total of 1,351 Japanese consecutive patients with neovascular age-related macular degeneration who were treated with brolucizumab from May 2020 to May 2022 at 14 institutions were examined. The variables analyzed were the number of brolucizumab injections, time to onset of IOI, and risk factors. Results: Intraocular inflammation developed in 152 eyes (11.3%). Retinal vasculitis and/or retinal occlusion occurred in 53 eyes (3.9%). Ninety-four patients received bilaterally, bilateral IOI occurred in five patients (5.3%). Sixteen eyes (1.2%) had irreversible visual acuity loss and nine eyes (0.67%) had visual loss of three lines or more due to retinal vasculitis and/or retinal occlusion. The cumulative IOI incidence was 4.5%, 10.3%, and 12.2% at 30, 180, and 365 days (1-year), respectively. History of IOI (including retinal vasculitis) and/or retinal occlusion (odds ratio [OR], 5.41; P = 0.0075) and female sex (OR, 1.99; P = 0.0004) were significantly associated with IOI onset. Conclusion: The 1-year cumulative incidence of IOI in Japanese neovascular age-related macular degeneration patients treated with brolucizumab was 12.2%. History of IOI (including retinal vasculitis) and/or retinal occlusion and female sex were significant risk factors.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 01 Apr 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:68:"RETINA. 44(4):714-722, April 2024. doi: 10.1097/IAE.0000000000004009";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202404000-00020";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:19;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:106:"https://journals.lww.com/retinajournal/fulltext/2018/11000/optimal_management_of_pigment_epithelial.1.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:91:"Khanani, Arshad M.; Eichenbaum, David; Schlottmann, Patricio G.; Tuomi, Lisa; Sarraf, David";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:6:"Review";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:110:"OPTIMAL MANAGEMENT OF PIGMENT EPITHELIAL DETACHMENTS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1718:"<a href="https://journals.lww.com/retinajournal/fulltext/2018/11000/optimal_management_of_pigment_epithelial.1.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-201811000-00001.T1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: This review aimed to determine the optimal management of retinal pigment epithelial detachments (PEDs) in neovascular age-related macular degeneration (nAMD) based on review of available evidence in the literature. Methods: A comprehensive literature review evaluates previous retrospective and prospective studies that assessed the treatment of PEDs in nAMD. Results: Studies illustrated that antiβvascular endothelial growth factor (VEGF) therapy can be effective in eyes with PED secondary to nAMD. Similar visual outcomes are associated with different anti-VEGF treatments. Higher anti-VEGF doses may improve anatomical response, without correlation with vision improvement. Fibrovascular PEDs may be difficult to treat, but even these eyes can gain vision with anti-VEGF therapy. A retinal pigment epithelial tear may develop in 15% to 20% of eyes with PEDs after anti-VEGF therapy, especially in PEDs greater than 500 Β΅m to 600 Β΅m in height; however, vision may stabilize with continued therapy. Atrophy may complicate eyes with PED and nAMD after anti-VEGF therapy, especially in association with complete PED resolution. Conclusion: Available literature suggests that anti-VEGF therapy is safe and efficacious for PED and nAMD. Treatment should focus on vision gains rather than PED resolution because there is no apparent correlation between anatomical and functional improvement in most eyes with PED and nAMD.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Thu, 01 Nov 2018 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:74:"RETINA. 38(11):2103-2117, November 2018. doi: 10.1097/IAE.0000000000002195";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-201811000-00001";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:20;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:113:"https://journals.lww.com/retinajournal/fulltext/2024/04000/tangential_retinal_displacement_increases_after.8.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:103:"Rossi, Tommaso; Querzoli, Giorgio; Cosimi, Pamela; Ripandelli, Guido; Steel, David H.; Romano, Mario R.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:92:"TANGENTIAL RETINAL DISPLACEMENT INCREASES AFTER MACULAR PUCKER SURGERY: An Apparent Nonsense";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2190:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/04000/tangential_retinal_displacement_increases_after.8.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202404000-00008.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To measure the tangential retinal displacement and vision before and after macular pucker surgery and study if pars plana vitrectomy with epiretinal membrane peeling allows the reconstitution of previous anatomy or else it results in a different configuration. Methods: Retrospective series of patients undergoing pars plana vitrectomy for epiretinal membrane, with >6-month follow-up before and after surgery, complete with best-corrected visual acuity, optical coherence tomography, M-Charts, and infrared retinography. Tangential retinal displacement between earliest visit (TE), time of surgery (T0), and latest available visit (TL) of the examined retina, concentric circles at 0.5, 1.5, and 4.5 mm radii, and the central horizontal and vertical meridians were measured. Tangential displacement was calculated as the optical flow of consecutive infrared photographs. Results: The study comprised 32 patients: 15 men and 17 women. Average preoperative and postoperative follow-up were 23.4 Β± 27.9 months and 19.2 Β± 11.8 months, respectively. Best-corrected visual acuity reduced before surgery (0.69 Β± 0.16 Snellen to 0.46 Β± 0.17; P < 0.001) and increased after (0.866 Β± 0.16 Snellen; P < 0.001). Horizontal and vertical metamorphopsia increased between before surgery but only horizontal metamorphopsia significantly reduced after. Average tangential displacement before surgery was 35.6 Β± 29.9 Β΅m versus 56.6 Β± 41.3 Β΅m after (P = 0.023). Preoperative and postoperative displacement within the fovea was less than over the entire area (P < 0.001). Conclusion: Retinal tangential displacement between diagnosis and surgery (TE β T0) is less than the displacement occurring after surgery (T0 β TL). Postoperative displacement does not represent the restoration of the anatomy existing before the disease ensued but rather the resulting equilibrium of newly deployed forces.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 01 Apr 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:68:"RETINA. 44(4):610-617, April 2024. doi: 10.1097/IAE.0000000000004001";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202404000-00008";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:21;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:108:"https://journals.lww.com/retinajournal/fulltext/2021/04000/particulate_matter_from_syringes_used_for.22.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:51:"Dounce, Susan M.; Laskina, Olga; Goldberg, Roger A.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:65:"PARTICULATE MATTER FROM SYRINGES USED FOR INTRAVITREAL INJECTIONS";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1785:"<a href="https://journals.lww.com/retinajournal/fulltext/2021/04000/particulate_matter_from_syringes_used_for.22.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202104000-00022.F1.jpeg" border="0" align ="left" alt="image"/></a>Background: Syringes containing anti-vascular endothelial growth factor drugs to treat retinal diseases are prepared in different ways by various parties with syringe selection, preparation, and storage conditions affecting the risk of injecting particles into the vitreous. This study examines particle loads from various syringes over time. Methods: Four syringes were studied: two plastic transfer syringes lubricated with silicone oil or oleamide, a glass syringe with baked-on silicone, and a lubricant-free polymer syringe. Syringes were rinsed with water or filled with buffer and analyzed over time; particles were quantified by flow imaging. Particle formation in a bevacizumab formulation was also characterized. Results: Insulin syringes consistently showed very high particle counts. Oleamide-lubricated syringes had substantially fewer particles, but showed appreciable increases over time (leading to visible particles). Baked-on silicone glass syringes and lubricant-free polymer syringes both showed low particle levels β₯10 ΞΌm. Lubricant-free syringes showed the lowest particle levels β₯1 ΞΌm and the lowest particle levels with bevacizumab agitation. Conclusion: Syringes have different intrinsic particle loads which can contribute to particle loads in the delivered drug. Oleamide-lubricated transfer syringes, commonly used for bevacizumab repackaging, have time-dependent particle loads and are associated with the formation of visible particles beyond 30 days of storage.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 21 Sep 2020 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:68:"RETINA. 41(4):827-833, April 2021. doi: 10.1097/IAE.0000000000002947";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202104000-00022";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:22;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:114:"https://journals.lww.com/retinajournal/fulltext/2024/05000/choroidal_vascularity_in_chronic_central_serous.11.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:119:"Kaye, Rebecca A.; Peto, Tunde; Hogg, Ruth; Griffiths, Helen; The VICI Trial Group; Sivaprasad, Sobha; Lotery, Andrew J.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:127:"CHOROIDAL VASCULARITY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY AND ITS ASSOCIATION WITH RISK SINGLE-NUCLEOTIDE POLYMORPHISMS";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1780:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/05000/choroidal_vascularity_in_chronic_central_serous.11.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202405000-00011.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To analyze the choroidal parameters of patients with chronic central serous chorioretinopathy (cCSC) and the association with central serous chorioretinopathy susceptibility genes. Methods: The choroidal vascular index (CVI) was obtained by binarizing spectral domain optical coherence tomography enhanced depth images of patients with cCSC and healthy age-matched controls. Patients with cCSC were genotyped for three central serous chorioretinopathy susceptibility single-nucleotide polymorphisms: rs4844392 (mir-29b-2/CD46), rs1329428 (CFH), and rs2379120 (upstream GATA5). Results: One hundred three eyes with cCSC and 53 control eyes were included. There was a significant increase in the subfoveal choroidal area in both the affected (2.4 Β± 0.6 mm2) and fellow (2.2 Β± 0.6 mm2) eyes of patients with cCSC compared with controls (1.8 Β± 0.5 mm2, P < 0.0001 and P < 0.0001). The CVI was reduced in patients with cCSC 63.5% Β± 3.1% compared with controls 65.4% Β± 2.3% (P < 0.001) and also in the affected compared with the fellow eyes 64.6% Β± 2.9% (P < 0.01). There was a significant association between CVI in the cCSC group and presence of the risk single-nucleotide polymorphisms rs2379120 at GATA5 (P < 0.01). Conclusion: The relative reduction of CVI in patients with cCSC may suggest a persistence of vessel hyperpermeability over dilation in chronic disease. GATA5 is associated with CVI in patients with cCSC and therefore may have a role in choroidal vascularity.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Thu, 18 Apr 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 44(5):837-843, May 2024. doi: 10.1097/IAE.0000000000004024";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202405000-00011";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:23;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:116:"https://journals.lww.com/retinajournal/fulltext/2024/05000/outcomes_of_infectious_panuveitis_associated_with.20.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:183:"Chau, Viet Q.; Hinkle, John W.; Wu, Chris Y.; Pakravan, Parastou; Volante, Vincent; Sengillo, Jesse D.; Staropoli, Patrick C.; Miller, Darlene; Yannuzzi, Nicolas A.; Albini, Thomas A.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:116:"OUTCOMES OF INFECTIOUS PANUVEITIS ASSOCIATED WITH SIMULTANEOUS MULTI-POSITIVE OCULAR FLUID POLYMERASE CHAIN REACTION";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1940:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/05000/outcomes_of_infectious_panuveitis_associated_with.20.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202405000-00020.T1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To evaluate features of infectious panuveitis associated with multiple pathogens detected by ocular fluid sampling. Methods: Single-center, retrospective, consecutive case series of patients with aqueous/vitreous polymerase chain reaction testing with >1 positive result in a single sample from 2001 to 2021. Results: Of 1,588 polymerase chain reaction samples, 28 (1.76%) were positive for two pathogens. Most common pathogens were cytomegalovirus (n = 16, 57.1%) and EpsteinβBarr virus (n = 13, 46.4%), followed by varicella zoster virus (n = 8, 28.6%), Toxoplasma gondii (n = 6, 21.4%), herpes simplex virus 2 (n = 6, 21.4%), herpes simplex virus 1 (n = 6, 21.4%), and Toxocara (n = 1, 3.6%). Mean initial and final visual acuity (logarithm of the minimum angle of resolution) were 1.3 Β± 0.9 (Snellen βΌ20/400) and 1.3 Β± 1.1 (Snellen βΌ20/400), respectively. Cytomegalovirus-positive eyes (n = 16, 61.5%) had a mean final visual acuity of 0.94 Β± 1.1 (Snellen βΌ20/175), whereas cytomegalovirus-negative eyes (n = 10, 38%) had a final visual acuity of 1.82 Β± 1.0 (Snellen βΌ20/1,320) (P < 0.05). Main clinical features included intraocular inflammation (100%), retinal whitening (84.6%), immunosuppression (65.4%), retinal hemorrhage (38.5%), and retinal detachment (34.6%). Conclusion: Cytomegalovirus or EpsteinβBarr virus were common unique pathogens identified in multi-PCRβpositive samples. Most patients with co-infection were immunosuppressed with a high rate of retinal detachment and poor final visual acuity. Cytomegalovirus-positive eyes had better visual outcomes compared with cytomegalovirus-negative eyes.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Thu, 18 Apr 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 44(5):909-915, May 2024. doi: 10.1097/IAE.0000000000004037";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202405000-00020";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:24;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:116:"https://journals.lww.com/retinajournal/fulltext/2018/09000/lean_six_sigma_techniques_to_improve_ophthalmology.6.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:126:"Ciulla, Thomas A.; Tatikonda, Mohan V.; ElMaraghi, Yehya A.; Hussain, Rehan M.; Hill, Amanda L.; Clary, Julie M.; Hattab, Eyas";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:68:"LEAN SIX SIGMA TECHNIQUES TO IMPROVE OPHTHALMOLOGY CLINIC EFFICIENCY";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1958:"<a href="https://journals.lww.com/retinajournal/fulltext/2018/09000/lean_six_sigma_techniques_to_improve_ophthalmology.6.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-201809000-00006.T1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: Ophthalmologists serve an increasing volume of a growing elderly population undergoing increasingly complex outpatient medical care, including extensive diagnostic testing and treatment. The resulting prolonged patient visit times (βpatient flow timesβ) limit quality, patient and employee satisfaction, and represent waste. Lean Six Sigma process improvement was used in a vitreoretinal practice to decrease patient flow time, demonstrating that this approach can yield significant improvement in health care. Methods: Process flow maps were created to determine the most common care pathways within clinic. Three months' visits from the electronic medical record system, which tracks patient task times at each process step in the office were collected. Care tasks and care pathways consuming the greatest time and variation were identified and modified. Follow-up analysis from 6 weeks' visits was conducted to assess improvement. Results: Nearly all patients took one of five paths through the office. Patient flow was redesigned to reduce waiting room time by having staff members immediately start patients into one of those five paths; staffing was adjusted to address high demand tasks, and scheduling was optimized around derived predictors of patient flow times. Follow-up analysis revealed a statistically significant decline in mean patient flow time by 18% and inpatient flow time SD by 4.6%. Patient and employee satisfaction scores improved. Conclusion: Manufacturing industry techniques, such as Lean and Six Sigma, can be used to improve patient care, minimize waste, and enhance patient and staff satisfaction in outpatient clinics.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Sat, 01 Sep 2018 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:74:"RETINA. 38(9):1688-1698, September 2018. doi: 10.1097/IAE.0000000000001761";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-201809000-00006";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:25;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:116:"https://journals.lww.com/retinajournal/fulltext/2022/06000/intravitreal_nesvacumab__antiangiopoietin_2__plus.13.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:229:"Brown, David M.; Boyer, David S.; Csaky, Karl; Vitti, Robert; Perlee, Lorah; Chu, Karen W.; Asmus, Friedrich; Leal, Sergio; Zeitz, Oliver; Cheng, Yenchieh; Schmelter, Thomas; Heier, Jeffrey S.; On behalf of the RUBY Investigators";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:118:"INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1665:"<a href="https://journals.lww.com/retinajournal/fulltext/2022/06000/intravitreal_nesvacumab__antiangiopoietin_2__plus.13.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202206000-00013.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: The purpose of this study was to compare intravitreal nesvacumab (anti-angiopoietin 2) plus aflibercept with intravitreal aflibercept injection (IAI) in diabetic macular edema. Methods: The eyes (n = 302) were randomized (1:2:3) to nesvacumab 3 mg + aflibercept 2 mg (LD combo), nesvacumab 6 mg + aflibercept 2 mg (HD combo), or IAI 2 mg at baseline, Weeks 4 and 8. LD combo continued every 8 weeks (q8w). HD combo was rerandomized at Week 12 to q8w or every 12 weeks (q12w); IAI to q8w, q12w, or HD combo q8w through Week 32. Results: Week 12 best-corrected visual acuity gains for LD and HD combo versus IAI were 6.8, 8.5, and 8.8 letters; Week 36 changes were similar. Central subfield retinal thickness reductions at Week 12 were β169.4, β184.0, and β174.6 Β΅m (nominal P = 0.0183, HD combo vs. IAI); Week 36 reductions for LD combo and HD combo q8w and q12w versus IAI were β210.4, β223.4, and β193.7 versus β61.9 Β΅m (nominal P < 0.05). At Week 12, 13.3% and 21.3% versus 15.2% had β₯2-step Diabetic Retinopathy Severity Scale improvement (LD and HD combos vs. IAI) and 59.6% and 66.3% versus 53.7% had complete foveal center fluid resolution. Safety was comparable across groups. Conclusion: Nesvacumab + aflibercept demonstrated no additional visual benefit over IAI. Anatomic improvements with HD combo may warrant further investigation.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Tue, 22 Feb 2022 00:00:00 GMT-06:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:69:"RETINA. 42(6):1111-1120, June 2022. doi: 10.1097/IAE.0000000000003441";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202206000-00013";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:26;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:114:"https://journals.lww.com/retinajournal/fulltext/2024/01000/high_myopia_is_common_in_patients_with_x_linked.16.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:64:"Huang, Li; Lai, Yanting; Sun, Limei; Li, Songshan; Ding, Xiaoyan";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:90:"HIGH MYOPIA IS COMMON IN PATIENTS WITH X-LINKED RETINOPATHIES: Myopic Maculopathy Analysis";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1655:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/01000/high_myopia_is_common_in_patients_with_x_linked.16.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202401000-00016.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: High myopia can occur as a single or syndromic condition. The aim of this study was to evaluate the refractive error and myopic maculopathy in patients with X-linked retinopathies. Methods: Whole exome sequencing, Sanger sequencing, and comprehensive ocular examinations were performed in patients with X-linked retinopathies. Results: A total of 17 patients were recruited, including six with CACNA1F, seven with RPGR, three with NYX, and one with OPN1MW mutations. The diagnoses were congenital stationary night blindness (6), coneβrod dystrophy (4), retinitis pigmentosa (4), achromatopsia (1), Leber congenital amaurosis (1), and myopia (1). Myopia was present in 88.2% patients, and 64.7% patients had high myopia. Gene analysis showed that high myopia was present in 80% patients with CACNA1F, 100% patients with NYX, and 57.1% patients with RPGR mutations. In the ATN classification, 64.7% of the patients were A1T0N0 and 35.3% were A0T0N0. The refractive errors progressed over time, even in patients with congenital stationary night blindness. Two females with heterozygous de novo RPGR mutations presented with retinitis pigmentosa or cone rod dystrophy combined with high myopia. Conclusion: High myopia is common in patients with X-linked retinopathies, and myopic maculopathy was only mild atrophy without traction and neovascularization.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 01 Jan 2024 00:00:00 GMT-06:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:70:"RETINA. 44(1):117-126, January 2024. doi: 10.1097/IAE.0000000000003934";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202401000-00016";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:27;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:114:"https://journals.lww.com/retinajournal/fulltext/2021/01000/clinical_characteristics_and_natural_history_of.25.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:455:"Nguyen, Xuan-Thanh-An; Talib, Mays; van Cauwenbergh, Caroline; van Schooneveld, Mary J.; Fiocco, Marta; Wijnholds, Jan; ten Brink, Jacoline B.; Florijn, Ralph J.; Schalij-Delfos, Nicoline E.; Dagnelie, Gislin; van Genderen, Maria M.; de Baere, Elfride; Meester-Smoor, Magda A.; De Zaeytijd, Julie; Balikova, Irina; Thiadens, Alberta A.; Hoyng, Carel B.; Klaver, Caroline C.; van den Born, L. Ingeborgh; Bergen, Arthur A.; Leroy, Bart P.; Boon, Camiel J.F.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:112:"CLINICAL CHARACTERISTICS AND NATURAL HISTORY OF RHO-ASSOCIATED RETINITIS PIGMENTOSA: A Long-Term Follow-Up Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1640:"<a href="https://journals.lww.com/retinajournal/fulltext/2021/01000/clinical_characteristics_and_natural_history_of.25.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202101000-00025.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To investigate the natural history of RHO-associated retinitis pigmentosa (RP). Methods: A multicenter, medical chart review of 100 patients with autosomal dominant RHO-associated RP. Results: Based on visual fields, time-to-event analysis revealed median ages of 52 and 79 years to reach low vision (central visual field <20Β°) and blindness (central visual field <10Β°), respectively. For the best-corrected visual acuity (BCVA), the median age to reach mild impairment (20/67 β€ BCVA < 20/40) was 72 years, whereas this could not be computed for lower acuities. Disease progression was significantly faster in patients with a generalized RP phenotype (n = 75; 75%) than that in patients with a sector RP phenotype (n = 25; 25%), in terms of decline rates of the BCVA (P < 0.001) and V4e retinal seeing areas (P < 0.005). The foveal thickness of the photoreceptorβretinal pigment epithelium (PR + RPE) complex correlated significantly with BCVA (Spearman's Ο = 0.733; P < 0.001). Conclusion: Based on central visual fields, the optimal window of intervention for RHO-associated RP is before the 5th decade of life. Significant differences in disease progression are present between generalized and sector RP phenotypes. Our findings suggest that the PR + RPE complex is a potential surrogate endpoint for the BCVA in future studies.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Wed, 15 Apr 2020 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:70:"RETINA. 41(1):213-223, January 2021. doi: 10.1097/IAE.0000000000002808";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202101000-00025";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:28;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:111:"https://journals.lww.com/retinajournal/fulltext/2020/06000/early_vitamin_a_supplementation_improves_the.23.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:41:"Sun, Huiqing; Cheng, Rui; Wang, Zhansheng";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:111:"EARLY VITAMIN A SUPPLEMENTATION IMPROVES THE OUTCOME OF RETINOPATHY OF PREMATURITY IN EXTREMELY PRETERM INFANTS";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1622:"<a href="https://journals.lww.com/retinajournal/fulltext/2020/06000/early_vitamin_a_supplementation_improves_the.23.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202006000-00023.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: This study assessed the efficacy and safety of early vitamin A (VA) supplementation to improve outcomes of retinopathy of prematurity in extremely preterm infants. Methods: A total of 262 eligible extremely preterm infants underwent randomization; of these, 132 were assigned to the VA group and 130 to the control group. The infants were administered a solution of VA (1,500 IU/day), added to their enteral feeds as soon as minimal feeding was introduced and continued for 28 days or until discharge. Results: With no adverse effects occurring, serum VA of the VA-supplemented infants on Days 14, 28, and postmenstrual 36 weeks was higher than that of the placebo group (P < 0.001). No signs of VA toxicity or increased intracranial pressure were reported. The VA group had lower unadjusted rates of Type 1 retinopathy of prematurity (1.6 vs. 6.9%, P = 0.030) and bronchopulmonary dysplasia (18.9 vs. 33.8%, P = 0.008) than the control group. Regression analysis revealed an association between serum VA levels and risk of Type 1 retinopathy of prematurity (beta = β2.37). Conclusion: Vitamin A supplementation reduced VA deficiency in extremely preterm infants; it was associated with a decreased incidence of Type 1 retinopathy of prematurity and may also have a positive impact on reducing bronchopulmonary dysplasia.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 01 Jun 2020 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:69:"RETINA. 40(6):1176-1184, June 2020. doi: 10.1097/IAE.0000000000002543";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202006000-00023";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:29;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:114:"https://journals.lww.com/retinajournal/fulltext/2021/09000/efficacy_and_safety_of_intravitreal_aflibercept.15.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:191:"Mitchell, Paul; Holz, Frank G.; Hykin, Philip; Midena, Edoardo; Souied, Eric; Allmeier, Helmut; Lambrou, George; Schmelter, Thomas; Wolf, Sebastian; on behalf of the ARIES study investigators";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:175:"EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2352:"<a href="https://journals.lww.com/retinajournal/fulltext/2021/09000/efficacy_and_safety_of_intravitreal_aflibercept.15.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202109000-00015.F1.jpeg" border="0" align ="left" alt="image"/></a>Background/Purpose: Treating neovascular age-related macular degeneration with intravitreal aflibercept treat-and-extend (T&E) can reduce treatment burden. ARIES assessed whether intravitreal aflibercept early-start T&E was noninferior to late-start T&E. Methods: A randomized, open-label, Phase 3b/4 study that included treatment-naΓ―ve patients aged β₯50 years with the best-corrected visual acuity 73β25 Early Treatment Diabetic Retinopathy Study letters and active choroidal neovascularization secondary to AMD. Patients received 2 mg intravitreal aflibercept at Week (W) 0, W4, W8, and W16. At W16, patients were randomized 1:1 to early-start (2W interval adjustments) or late-start T&E (8W intervals until W48 then 2W interval adjustments). Primary endpoint: the best-corrected visual acuity change from randomization to W104. Results: Two-hundred seventy-one patients were randomized. The mean (SD) best-corrected visual acuity at baseline was 60.2 (12.1; early-T&E) and 61.3 (10.8; late-T&E) letters. The mean (SD) best-corrected visual acuity change (W16β104) was β2.1 (11.4) versus β0.4 (8.4) letters (early-T&E vs. late-T&E; least-squares mean difference: β2.0; 95% confidence interval: β4.75 to 0.71; P = 0.0162 for noninferior); +4.3 (13.4) versus +7.9 (11.9) letters (W0β104). The mean (SD) number of injections was 12.0 (2.3) versus 13.0 (1.8). From baseline to W104, 93.4% and 96.2% maintained best-corrected visual acuity; the mean (SD) central retinal thickness change was β161.6 (135.6) Β΅m and β158.6 (125.1) Β΅m. The last injection interval (W104) was β₯12W for 47.2% and 51.9% of patients. Conclusion: Outcomes were similar between patients with neovascular age-related macular degeneration treated with an intravitreal aflibercept early-T&E or late-T&E regimen after initial dosing, with one injection difference over 2 years. Trial Registration: ClinicalTrials.gov Identifier: NCT02581891 https://clinicaltrials.gov/ct2/show/NCT02581891. Supplemental Digital Contents (files 1 http://links.lww.com/IAE/B419).";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Wed, 01 Sep 2021 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:74:"RETINA. 41(9):1911-1920, September 2021. doi: 10.1097/IAE.0000000000003128";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202109000-00015";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:30;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:116:"https://journals.lww.com/retinajournal/fulltext/2024/05000/sf6_compared_with_c2f6_for_inferior_rhegmatogenous.6.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:211:"Moussa, George; Jalil, Assad; Lippera, Myrta; Cristescu, Irina-Elena; Ferrara, Mariantonia; Ally, Naseer; Ziaei, Hadi; El-Faouri, Muhannd; Patton, Niall; Jasani, Kirti M.; Dhawahir-Scala, Felipe; Ivanova, Tsveta";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:119:"SF6 COMPARED WITH C2F6 FOR INFERIOR RHEGMATOGENOUS RETINAL REPAIR: The Manchester Pseudophakic Retinal Detachment Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2173:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/05000/sf6_compared_with_c2f6_for_inferior_rhegmatogenous.6.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202405000-00006.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To compare SF6 relative with C2F6 in the anatomical and functional outcomes following pars plana vitrectomy for uncomplicated primary pseudophakic rhegmatogenous retinal detachment with inferior causative breaks. Methods: This is a retrospective, comparative study on eyes with pseudophakic rhegmatogenous retinal detachment with inferior causative breaks that had small-gauge pars plana vitrectomy repair using SF6 and C2F6 tamponade between 2011 and 2020 at a tertiary centre in the United Kingdom. Primary outcome was single surgery anatomical success, and the secondary outcome was best-corrected visual acuity. Propensity score matching, using preoperative findings as covariates to account for relevant confounders, was performed. Results: From 162 pseudophakic rhegmatogenous retinal detachment eyes with inferior causative breaks, the median (interquartile range) follow-up was 82 (52β182) days. The single surgery anatomical success was 156 (96.3%) overall: 47 of 47 (100.0%) and 109 of 115 (94.8%) in the SF6 and C2F6 groups, respectively (P = 0.182). Relative to the SF6 group, the C2F6 group had a higher mean number of tears (SF6: 3.1[2.0], C2F6: 4.5[2.7], P = 0.002) and greater retinal detachment extent (SF6: 5.3[2.9], C2F6: 6.2[2.6] clock hours, P = 0.025). Following propensity score matching analysis, 80 eyes were matched with 40 in each group to homogenize preoperative factors. No significant difference was found in single surgery anatomical success and best-corrected visual acuity between the groups following propensity score matching. Conclusion: Primary pars plana vitrectomy with gas tamponade leads to a high single surgery anatomical success rate in uncomplicated pseudophakic rhegmatogenous retinal detachment with inferior causative breaks with no additional benefit associated with long-acting tamponade when comparing C2F6 with SF6.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Wed, 01 May 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 44(5):791-798, May 2024. doi: 10.1097/IAE.0000000000004051";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202405000-00006";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:31;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:107:"https://journals.lww.com/retinajournal/fulltext/2024/05000/postoperative_photoreceptor_integrity_and.2.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:121:"El-Sehemy, Ahmed; Martins Melo, Isabela; Pecaku, Aurora; Zajner, Chris; Naidu, Sumana; Motekalem, Yasmin; Muni, Rajeev H.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:136:"POSTOPERATIVE PHOTORECEPTOR INTEGRITY AND ANATOMICAL OUTCOMES BASED ON PRESENTING MORPHOLOGIC STAGE OF RHEGMATOGENOUS RETINAL DETACHMENT";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1885:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/05000/postoperative_photoreceptor_integrity_and.2.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202405000-00002.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To evaluate outer retinal recovery on postoperative optical coherence tomography (OCT) based on presenting morphologic stage of rhegmatogenous retinal detachment (RRD). Methods: Retrospective cohort of consecutive primary fovea-involving RRDs, referred from January 2012 to September 2022. Baseline OCTs were assessed for morphologic stage of RRD. Postoperative OCT scans were graded at 3, 6, and 12 months for external limiting membrane, ellipsoid zone and interdigitation zone discontinuity, epiretinal membrane formation and severity, and residual subfoveal fluid. Results: Three hundred and fifty-one patients were included. Increasing baseline morphologic stage of RRD was significantly associated with external limiting membrane, ellipsoid zone, and interdigitation zone discontinuity at all time points postoperatively (P < 0.001) and was shown to be an independent predictor of foveal photoreceptor integrity after adjusting for height of detachment, time to surgery, and duration of fovea involvement (P < 0.001). Earlier stages were associated with residual subfoveal fluid (P < 0.001). There was no association between the stages of RRD and epiretinal membrane severity. However, late stages presented with earlier development of epiretinal membrane (P = 0.012). Conclusion: Increasing morphologic stage of RRD is associated with delayed recovery of outer retinal bands in the first year and faster development of epiretinal membrane after RRD repair. The results of this study suggest that the stages may serve as a prognostic biomarker for postoperative photoreceptor recovery.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Wed, 01 May 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 44(5):756-763, May 2024. doi: 10.1097/IAE.0000000000004034";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202405000-00002";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:32;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:113:"https://journals.lww.com/retinajournal/fulltext/2022/03000/the_rap_study,_report_5__rediscovering_macular.10.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:112:"Haj Najeeb, Bilal; Deak, Gabor G.; Mylonas, Georgios; Sacu, Stefan; Gerendas, Bianca S.; Schmidt-Erfurth, Ursula";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:122:"THE RAP STUDY, REPORT 5: REDISCOVERING MACULAR NEOVASCULARIZATION TYPE 3: Multimodal Imaging of Fellow Eyes over 24 months";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1958:"<a href="https://journals.lww.com/retinajournal/fulltext/2022/03000/the_rap_study,_report_5__rediscovering_macular.10.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202203000-00010.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To explore the condition of fellow eyes of patients with macular neovascularization Type 3 (MNV3) and to verify whether the retinalβchoroidal anastomosis (RCA) develops equally in all MNV types. Methods: The contralateral eyes of 94 patients with MNV3, 96 patients with MNV1, and 96 patients with MNV2 were included. Multimodal imaging was performed. The MNV3 stage including the development of fibrosis and RCA over 24 months was determined. Results: In the contralateral eyes of patients of the solitary (one lesion) MNV3 group, 32 eyes (42.1%) showed early/intermediate age-related macular degeneration, 25 eyes (33%) showed MNV3, and 11 eyes (14.5%) experienced fibrosis, of which 4 eyes (5.2%) had a RCA, 7 eyes (9.2%) had atrophy after resolved MNV3, and 1 eye (1.3%) developed MNV1. In the multifocal (more than one lesion) MNV3 group, 2 eyes (11.1%) showed early/intermediate age-related macular degeneration, 9 eyes (50%) showed 15 MNV3 lesions, and 4 eyes (22.2%) showed fibrosis, of which 2 eyes (11.1%) manifested with a RCA and 3 eyes (16.7%) showed atrophy after resolved MNV3. The number of eyes with a RCA accounted for 40% of all eyes with fibrosis. The count of simultaneous bilateral multifocal MNV3 was 5 (55.6%). In the MNV1 and MNV2 groups, no eye developed a RCA. The incidence of RCAs in the scarred eyes in MNV3 was significantly higher (P < 0.0001). Conclusion: Retinalβchoroidal anastomosis is an exclusive clinical feature of MNV3. The development of the multifocal MNV3 is usually bilateral and simultaneous. The occurrence of fibrosis in MNV3 has decreased dramatically after the introduction of the antiangiogenic therapy.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 18 Oct 2021 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:68:"RETINA. 42(3):485-493, March 2022. doi: 10.1097/IAE.0000000000003330";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202203000-00010";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:33;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:114:"https://journals.lww.com/retinajournal/fulltext/2024/05000/additional_pneumatic_retinopexy_in_patients_with.7.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:60:"Jung, Young Hoon; Woo, Se Joon; Joo, Kwangsic; Kim, Min Seok";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:101:"ADDITIONAL PNEUMATIC RETINOPEXY IN PATIENTS WITH PERSISTENT RETINAL DETACHMENT AFTER SCLERAL BUCKLING";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1797:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/05000/additional_pneumatic_retinopexy_in_patients_with.7.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202405000-00007.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To investigate the efficacy, safety, and indications for additional pneumatic retinopexy (PR) in patients with persistent retinal detachment after scleral buckling. Methods: This retrospective study included patients who underwent additional PR after scleral buckling for primary rhegmatogenous retinal detachment (n = 78). We defined βinadequate buckleβ as retinal detachment persistence because of low buckle height despite accurate buckle placement and βbuckle misplacementβ as an uncovered tear because of incorrect buckle placement. Results: The anatomical success rate after additional PR was 52.6%. Development of proliferative vitreoretinopathy Grade B (hazard ratio, 5.73; P < 0.001) and inferior retinal tears (hazard ratio, 2.12; P = 0.040) were significant risk factors for anatomical failure. The most common cause of anatomical failure was proliferative vitreoretinopathy (19 of 37; 51.4%), and epiretinal membrane formation was a common complication after additional PR (22 of 78; 28.2%). The anatomical success rate with additional PR was significantly higher in the inadequate buckle group than in the misplacement group (8 of 9 [88.9%] vs. 1228 [42.9%]; P = 0.023). Conclusion: Development of proliferative vitreoretinopathy Grade B and inferior retinal tears were significantly associated with anatomical failure after additional PR. Additional PR may benefit patients with superior retinal tears or low buckle height and those without proliferative vitreoretinopathy.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Wed, 01 May 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 44(5):799-809, May 2024. doi: 10.1097/IAE.0000000000004055";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202405000-00007";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:34;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:114:"https://journals.lww.com/retinajournal/fulltext/2023/11000/multizonal_outer_retinopathy_and_retinal_pigment.8.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:133:"Ramtohul, Prithvi; Marchese, Alessandro; Introini, Ugo; Goldstein, Debra A.; Freund, K. Bailey; Jampol, Lee M.; Yannuzzi, Lawrence A.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:129:"MULTIZONAL OUTER RETINOPATHY AND RETINAL PIGMENT EPITHELIOPATHY (MORR): A Newly Recognized Entity or an Unusual Variant of AZOOR?";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1981:"<a href="https://journals.lww.com/retinajournal/fulltext/2023/11000/multizonal_outer_retinopathy_and_retinal_pigment.8.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202311000-00008.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To describe specific clinical, multimodal imaging, and natural history features of an unusual variant of acute zonal occult outer retinopathy. Methods: Retrospective, observational, longitudinal, multicenter case series. Patients exhibiting this unusual clinical condition among cases previously diagnosed with acute zonal occult outer retinopathy were included. Multimodal imaging, laboratory evaluations, and genetic testing for inherited retinal diseases were reviewed. Results: Twenty eyes from 10 patients (8 females and 2 males) with a mean age of 54.1 Β± 13.3 years (range, 38β71 years) were included. The mean follow-up duration was 13.1 Β± 5.3 years (range, 8β23 years). Presenting symptoms were bilateral in 7 patients (85% of eyes) and included scotomata and photopsia. All patients had bilateral lesions at presentation involving the peripapillary and far peripheral retina. Baseline optical coherence tomography showed alteration of the retinal pigment epithelium and photoreceptor layers corresponding to zonal areas of fundus autofluorescence abnormalities. Centrifugal and centripetal progression of the peripapillary and far-peripheral lesions, respectively, occurred over the follow-up, resulting in areas of complete outer retinal and retinal pigment epithelium atrophy. Conclusion: Initial alteration of photoreceptors and retinal pigment epithelium and a stereotypical natural course that includes involvement of the far retinal periphery, characterize this unusual condition. It may represent a variant of acute zonal occult outer retinopathy or may be a new entity. We suggest to call it multizonal outer retinopathy and retinal pigment epitheliopathy.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Thu, 19 Oct 2023 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:74:"RETINA. 43(11):1890-1903, November 2023. doi: 10.1097/IAE.0000000000003927";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202311000-00008";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:35;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:116:"https://journals.lww.com/retinajournal/fulltext/2022/07000/comparison_between_scleral_buckling_and_vitrectomy.7.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:140:"Gharbiya, Magda; Visioli, Giacomo; Iannetti, Ludovico; Iannaccone, Andrea; Tamburrelli, Anna Clara; Marenco, Marco; Albanese, Giuseppe Maria";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:159:"COMPARISON BETWEEN SCLERAL BUCKLING AND VITRECTOMY IN THE ONSET OF CYSTOID MACULAR EDEMA AND EPIRETINAL MEMBRANE AFTER RHEGMATOGENOUS RETINAL DETACHMENT REPAIR";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2158:"<a href="https://journals.lww.com/retinajournal/fulltext/2022/07000/comparison_between_scleral_buckling_and_vitrectomy.7.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202207000-00007.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To investigate the incidence and risk factors for the main complications in patients with rhegmatogenous retinal detachment treated with scleral buckling (SB) or pars plana vitrectomy (PPV). Methods: A retrospective, comparative, observational study was conducted. The medical records of 107 patients with primary rhegmatogenous retinal detachment who were managed with SB (n = 57) or PPV (n = 50) were reviewed. Scleral buckling was performed using scleral encircling solid silicone band and circumferential solid silicone exoplant to support the break. Pars plana vitrectomy was combined with phacoemulsification in phakic eyes and with scleral encircling in inferior detachments. Follow-ups, including spectral-domain optical coherence tomography examination, were scheduled at 1, 3, and 12 months after surgery. Propensity score matching was used to adjust for potential preoperative selection bias. Results: The overall incidence of postoperative cystoid macular edema (CME) and epiretinal membrane was 14.95% and 30.84%, respectively. Compared with SB, CME was more frequent in the PPV (P = 0.021) and in the PPV pseudophakic eyes (P = 0.027). Postoperative CME was an early, predominantly transient complication and regressed in 67% of SB and in 77% of PPV eyes within 12 months after surgery. No differences were observed regarding epiretinal membrane development. Except for the surgical technique, no preoperative factors associated with CME were identified. A correlation between epiretinal membrane and patients' age was found (P = 0.028). Conclusion: The incidence of CME after rhegmatogenous retinal detachment repair was higher in patients who underwent PPV, either alone or combined with phacoemulsification, than in those treated with SB. Epiretinal membrane development was correlated to older age, regardless of the surgical procedure.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Fri, 11 Mar 2022 00:00:00 GMT-06:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:69:"RETINA. 42(7):1268-1276, July 2022. doi: 10.1097/IAE.0000000000003475";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202207000-00007";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:36;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:111:"https://journals.lww.com/retinajournal/fulltext/2023/07000/complement_inhibition_for_geographic_atrophy_.2.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:40:"Spaide, Richard F.; Vavvas, Demetrios G.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:99:"COMPLEMENT INHIBITION FOR GEOGRAPHIC ATROPHY: Review of Salient Functional Outcomes and Perspective";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2116:"<a href="https://journals.lww.com/retinajournal/fulltext/2023/07000/complement_inhibition_for_geographic_atrophy_.2.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202307000-00002.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To evaluate available rationale and outcomes of randomized trial results for complement inhibition for geographic atrophy. Methods: Data from recently completed randomized trials of complement inhibition, particularly for pegcetacoplan and avacincaptad pegol, were evaluated for both the outcome, area of autofluorescence loss, and functional vision tests. Results: Pegcetacoplan 2 mg showed statistically significant reduction in expansion of the area of autofluorescence loss with monthly, but not every-other-month dosing, in a 12-month phase two trial. Nearly 40% of patients recruited for the monthly arm did not complete the treatment. In two parallel phase 3 studies there was a statistically significant reduction in the area of atrophy in one but not both studies as compared with untreated controls. Data released at 24 months follow-up showed statistically significant reduction in the area of autofluorescence-detected atrophy in both studies compared with sham. Patients did not show functional difference in best-corrected visual acuity, maximum reading speed, Functional Reading Independence Index, and mean microperimetry threshold sensitivities in the treatment versus sham arms. Avacincaptad pegol was evaluated in two randomized pivotal studies and showed a statistically significant reduction in the expansion of autofluorescence loss at 12 months. Patients in the treatment arms did not show any difference as compared with sham in the best-corrected visual acuity or low luminance visual acuity, the only functional outcomes mentioned. Both drugs increased the risk of macular neovascularization. Conclusion: Both avacincaptad pegol and pegcetacoplan show significant differences compared with sham in autofluorescence imaging but no benefit in visual function at 12 and 24 months, respectively.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Sat, 01 Jul 2023 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:69:"RETINA. 43(7):1064-1069, July 2023. doi: 10.1097/IAE.0000000000003796";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202307000-00002";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:37;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:111:"https://journals.lww.com/retinajournal/fulltext/2021/05000/diabetic_macular_edema_and_cataract_surgery_.26.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:144:"Furino, Claudio; Boscia, Francesco; Niro, Alfredo; D'Addario, Maria; Grassi, Maria O.; Saglimbene, Valeria; Reibaldi, Michele; Alessio, Giovanni";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:156:"DIABETIC MACULAR EDEMA AND CATARACT SURGERY: Phacoemulsification Combined With Dexamethasone Intravitreal Implant Compared With Standard Phacoemulsification";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2241:"<a href="https://journals.lww.com/retinajournal/fulltext/2021/05000/diabetic_macular_edema_and_cataract_surgery_.26.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202105000-00026.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To compare functional and anatomical results of combined phacoemulsification and dexamethasone intravitreal implant (Ozurdex; DEX-I) with standard phacoemulsification in diabetic patients with cataract. Methods: Retrospective, comparative, cohort study. Patients with nonproliferative diabetic retinopathy, macular edema, and cataract, treated routinely at the Eye Clinic, Azienda Ospedaliero Universitaria Policlinico, Bari, Italy with phacoemulsification associated with DEX-I (n = 23; Phaco-Dex) or standard phacoemulsification (n = 23; Phaco-alone). Best-correct visual acuity, central subfield thickness, and intraocular pressure were assessed at baseline and monthly for 3 months after surgery, and t-test was used to assess change from baseline. A multilevel regression model with an unstructured correlation-type matrix to account for repeated data measures was used for statistical analysis in and between groups. Results: With Phaco-Dex, best-correct visual acuity increased significantly from the first month (P = 0.0005 vs. baseline) and remained stable at the following visits; central subfield thickness decreased significantly from Month 2 (P = 0.049 and P = 0.04 vs. baseline, respectively); at each timepoint, central subfield thickness was significantly lower in the Phaco-Dex group versus Phaco-alone. Intraocular pressure increased significantly during follow-up (P = 0.001 at Month 3 vs. baseline) but remained within the normal range. In the Phaco-alone group, best-correct visual acuity, and intraocular pressure did not show any significant changes after surgery, whereas central subfield thickness increased from Month 2 (P = 0.05 vs. baseline). Conclusion: In diabetic patients with macular edema and visually significant cataract, combined treatment with phacoemulsification and DEX-I seemed to be effective, safe, and superior to standard phacoemulsification considering both functional and tomographic parameters.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Thu, 22 Apr 2021 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:68:"RETINA. 41(5):1102-1109, May 2021. doi: 10.1097/IAE.0000000000002974";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202105000-00026";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:38;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:114:"https://journals.lww.com/retinajournal/fulltext/2021/01000/revised_classification_of_the_optical_coherence.21.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:34:"Bloom, Steven M.; Singal, Inder P.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:129:"REVISED CLASSIFICATION OF THE OPTICAL COHERENCE TOMOGRAPHY OUTER RETINAL BANDS BASED ON CENTRAL SEROUS CHORIORETINOPATHY ANALYSIS";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1916:"<a href="https://journals.lww.com/retinajournal/fulltext/2021/01000/revised_classification_of_the_optical_coherence.21.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202101000-00021.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To evaluate the optical coherence tomography (OCT) imaging findings in recent onset neurosensory retinal detachments induced by central serous chorioretinopathy and to attempt to corroborate these findings with proposed anatomical correlates. Methods: Retinal detachments due to central serous chorioretinopathy of less than 3 months' duration and the surrounding area were scanned with OCT. The imaging of the outer retinal bands was evaluated according to proposals by Cuenca et al and the INβ’OCT Consensus classification. Results: Optical coherence tomography findings in 11 eyes (11 patients) with CSC showed that all hyperreflective bands above Band 4 were variably continuous within the outer portion of the serous detachment. We then attempted to reconcile inconsistencies in current explanations for the outer retinal bands to propose changes to the outer retinal OCT nomenclature. Conclusion: Our patients' OCT findings support the current standard that Band 3 is an outer retinal structure and that Band 4 represents the retinal pigment epithelium/Bruch complex. Confusion exists regarding whether the interdigitation zone extends halfway up or for the full length of the outer segments, and the hyporeflective band between Bands 3 and 4 has yet to receive an appropriate term. We therefore propose a modification to the INβ’OCT Consensus classification by renaming the trilaminar hyporeflective, hyperreflective, and hyporeflective bands between Bands 2 and 4 as the outer segmentβinterdigitation zone complex consisting of the inner, middle, and outer segmentβinterdigitation zone, respectively.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Wed, 08 Apr 2020 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:70:"RETINA. 41(1):181-188, January 2021. doi: 10.1097/IAE.0000000000002792";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202101000-00021";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:39;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:106:"https://journals.lww.com/retinajournal/fulltext/2021/05000/leber_congenital_amaurosis_due_to_cep290.2.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:145:"Leroy, Bart P.; Birch, David G.; Duncan, Jacque L.; Lam, Byron L.; Koenekoop, Robert K.; Porto, Fernanda B. O.; Russell, Stephen R.; Girach, Aniz";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:6:"Review";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:118:"LEBER CONGENITAL AMAUROSIS DUE TO CEP290 MUTATIONSβSEVERE VISION IMPAIRMENT WITH A HIGH UNMET MEDICAL NEED: A Review";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1749:"<a href="https://journals.lww.com/retinajournal/fulltext/2021/05000/leber_congenital_amaurosis_due_to_cep290.2.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202105000-00002.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: Leber congenital amaurosis due to CEP290 mutations (LCA10) is an inherited retinal disease that often results in severe visual impairment or blindness in early childhood. Currently, there are no approved treatments, highlighting the considerable unmet medical need associated with LCA10. We aimed to review the clinical characteristics of LCA10, its impact on patients and society, and the investigational treatment strategies currently in development. Methods: Review of the current literature. Results: LCA10 is an autosomal recessive ciliopathy, for which the CEP290 intronic variant c.2991+1655A>G (p.Cys998X) is the most common mutation. Usually diagnosed in early childhood, most patients with LCA10 have severe visual impairment during their first decade of life, which significantly affects the quality of life and development. LCA10 also has a significant societal burden (direct and indirect costs). RNA editing using antisense oligonucleotides or Staphylococcus aureus CRISPR-associated protein-9 nuclease is currently under investigation for treatment of p.Cys998X LCA10. Specifically, the antisense oligonucleotide therapy QR-110 (sepofarsen) has demonstrated encouraging safety and efficacy data in a first-in-human trial; a phase 3 clinical trial is ongoing. Conclusion: Interventions that can preserve or improve vision in patients with LCA10 have considerable potential to improve the patient quality of life and reduce burden of disease.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Tue, 16 Feb 2021 00:00:00 GMT-06:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 41(5):898-907, May 2021. doi: 10.1097/IAE.0000000000003133";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202105000-00002";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:40;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:115:"https://journals.lww.com/retinajournal/fulltext/2024/04000/a_novel_embedded_style_corneal_contact_lens__for.24.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:64:"Liu, Yajun; Lei, Huangyi; Guo, Yinong; Bao, Yanbo; Xie, Zhenggao";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:15:"New Instruments";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:122:"A NOVEL EMBEDDED-STYLE CORNEAL CONTACT LENS: For Emergency Vitreoretinal Surgery in Patients with Severe Corneal Opacities";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:290:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/04000/a_novel_embedded_style_corneal_contact_lens__for.24.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202404000-00024.F1.jpeg" border="0" align ="left" alt="image"/></a>No abstract available";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 01 Apr 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:68:"RETINA. 44(4):744-746, April 2024. doi: 10.1097/IAE.0000000000004074";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202404000-00024";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:41;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:105:"https://journals.lww.com/retinajournal/fulltext/2022/12000/anti_vascular_endothelial_growth_factor.1.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:67:"Kaiser, Peter K.; Schmitz-Valckenberg, Marc Steffen; Holz, Frank G.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:6:"Review";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:70:"ANTIβVASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1613:"<a href="https://journals.lww.com/retinajournal/fulltext/2022/12000/anti_vascular_endothelial_growth_factor.1.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202212000-00001.F1.jpeg" border="0" align ="left" alt="image"/></a>Background/Purpose: Antiβvascular endothelial growth factor therapies have proven effective in treating retinal diseases but come with a high financial burden to the patient and health care system. Biosimilar drugs present an opportunity to decrease the cost of these important ophthalmic medications, and several ophthalmic biosimilars are expected to be approved and enter the market in the coming years. The objectives of this review are to educate ophthalmologists on the safety and efficacy of biosimilars in ophthalmology in the United States and European Union, review the biosimilar manufacturing and approval process, and describe the upcoming ophthalmic biosimilars. Results: Two ranibizumab biosimilars are currently approved in the United States and European Union. Additional ranibizumab biosimilars, as well as biosimilars for aflibercept and bevacizumab, are currently in clinical development. Conclusion: Biosimilar use in ophthalmology is expected to grow with the patent expiration of two major antiβvascular endothelial growth factor drugs, ranibizumab and aflibercept, and the development of an ophthalmology-specific bevacizumab biosimilar. Financial savings from biosimilar use in ophthalmology have the potential to reduce economic burden, increase treatment adherence, and ultimately improve health outcomes.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Tue, 15 Nov 2022 00:00:00 GMT-06:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:74:"RETINA. 42(12):2243-2250, December 2022. doi: 10.1097/IAE.0000000000003626";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202212000-00001";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:42;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:102:"https://journals.lww.com/retinajournal/fulltext/2013/09000/pachychoroid_pigment_epitheliopathy.22.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:51:"Warrow, David J.; Hoang, Quan V.; Freund, K. Bailey";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:35:"PACHYCHOROID PIGMENT EPITHELIOPATHY";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2114:"<a href="https://journals.lww.com/retinajournal/fulltext/2013/09000/pachychoroid_pigment_epitheliopathy.22.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-201309000-00022.T1-22.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To report nine cases of pachychoroid pigment epitheliopathy. Methods: An observational case series of nine patients who underwent comprehensive ophthalmic examination, fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, and enhanced depth imaging optical coherence tomography. Results: Eighteen eyes of 9 patients, aged 27 years to 89 years, were diagnosed with pachychoroid pigment epitheliopathy based on the characteristic funduscopic appearance of reduced fundus tessellation with overlying retinal pigment epithelial changes in one or both eyes, fundus autofluorescence abnormalities, and increased subfoveal choroidal thickness confirmed by enhanced depth imaging optical coherence tomography (mean, 460.2 ΞΌm). The five older patients had been previously diagnosed with age-related macular degeneration, while the four younger subjects were referred for possible inflammatory chorioretinitis, pattern dystrophy, or nonspecific drusen. No subjects had a history of or subsequently developed subretinal fluid. Conclusion: Pachychoroid pigment epitheliopathy falls within a spectrum of diseases associated with choroidal thickening that includes central serous chorioretinopathy and polypoidal choroidal vasculopathy, and it should be suspected in eyes with a characteristic fundus appearance related to choroidal thickening and associated retinal pigment epithelial abnormalities but no history of subretinal fluid. Enhanced depth imaging optical coherence tomography confirming an abnormally thick choroid and characteristic retinal pigment epithelial changes on fundus autofluorescence support the diagnosis. Because these patients are frequently misdiagnosed, the recognition of pachychoroid pigment epitheliopathy may avoid unnecessary diagnostic testing and interventions.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Sun, 01 Sep 2013 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:74:"RETINA. 33(8):1659-1672, September 2013. doi: 10.1097/IAE.0b013e3182953df4";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-201309000-00022";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:43;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:112:"https://journals.lww.com/retinajournal/fulltext/2021/11000/an_association_between_stellate_nonhereditary.21.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:146:"Bloch, Edward; Flores-SΓ‘nchez, Blanca; Georgiadis, Odysseas; Sundaram, Venki; Saihan, Zubin; Mahroo, Omar A.; Webster, Andrew R.; da Cruz, Lyndon";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:143:"AN ASSOCIATION BETWEEN STELLATE NONHEREDITARY IDIOPATHIC FOVEOMACULAR RETINOSCHISIS, PERIPHERAL RETINOSCHISIS, AND POSTERIOR HYALOID ATTACHMENT";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1950:"<a href="https://journals.lww.com/retinajournal/fulltext/2021/11000/an_association_between_stellate_nonhereditary.21.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202111000-00021.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: Stellate nonhereditary idiopathic foveomacular retinoschisis is a disorder characterized by splitting of the retina at the macula, without a known underlying mechanical or inherited cause. This study investigates demographic, anatomical, and functional characteristics of subjects with stellate nonhereditary idiopathic foveomacular retinoschisis, to explore potential underlying mechanisms. Methods: In this single-site, retrospective, and cross-sectional, observational study, data were collected from 28 eyes from 24 subjects with stellate nonhereditary idiopathic foveomacular retinoschisis. Descriptive statistics were reported, based on the observed anatomico-functional features. Results: The visual acuity remained stable (median 20/20) in all subjects over a median follow-up of 17 months. All cases demonstrated foveomacular retinoschisis within Henle's fiber layer, at the junction of the outer plexiform and outer nuclear layers. This schisis cavity extended beyond the limits of the macular OCT temporally in all eyes. In most affected eyes, there were documented features of peripheral retinoschisis and broad attachment of the posterior hyaloid at the macula. Functional testing in a cross-sectional subset demonstrated normal retinal sensitivity centrally but an absolute scotoma peripherally. Conclusion: Stellate nonhereditary idiopathic foveomacular retinoschisis seems to be associated with peripheral retinoschisis and anomalous or incomplete posterior hyaloid detachment. Despite chronic manifestation, this does not significantly affect central visual function but can manifest with profound loss of peripheral visual function.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 01 Nov 2021 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:74:"RETINA. 41(11):2361-2369, November 2021. doi: 10.1097/IAE.0000000000003191";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202111000-00021";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:44;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:115:"https://journals.lww.com/retinajournal/fulltext/2024/05000/retinal_microvasculopathy_with_different_insulin.18.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:53:"Guo, Yan; Zheng, Xiaoquan; He, Hongwu; Zheng, Suilian";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:147:"RETINAL MICROVASCULOPATHY WITH DIFFERENT INSULIN INFUSION THERAPIES IN CHILDREN WITH TYPE 1 DIABETES MELLITUS WITHOUT CLINICAL DIABETIC RETINOPATHY";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2236:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/05000/retinal_microvasculopathy_with_different_insulin.18.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202405000-00018.T1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To explore the characteristics and associated factors of retinal microvasculopathy and neurodegeneration with different insulin therapies in children with type 1 diabetes mellitus (T1DM) but without diabetic retinopathy. Methods: Forty-one children with T1DM with multiple daily insulin injections (MDI), 22 children with T1DM with continuous subcutaneous insulin infusion, and 62 age-matched normal control children were enrolled. SPECTRALIS Optical coherence tomography was used to scan 6Γ6 mm square area of posterior retina. Results: The vessel density of superficial vascular plexus, intermediate capillary plexus, and deep capillary plexus in T1DM-MDI group were all significantly lower than those in the T1DM-CSII and control groups (0.39 Β± 0.05 vs. 0.44 Β± 0.04 and 0.42 Β± 0.06, P < 0.001; 0.26 Β± 0.04 vs. 0.30 Β± 0.02 and 0.28 Β± 0.04, P = 0.003; 0.30 Β± 0.04 vs. 0.33 Β± 0.04 and 0.32 Β± 0.04, P = 0.027). In T1DM-MDI group, lower vessel density of superficial vascular plexus was associated with higher hemoglobin A1c (r = β0.377, P = 0.015). Foveal avascular zone morphology index in T1DM-MDI and T1DM-CSII groups were smaller than that in the control group (0.63 Β± 0.11 and 0.63 Β± 0.12 vs. 0.69 Β± 0.15, P = 0.040). There was no statistically significant difference in the thickness of the retina among the three groups (P > 0.05). Conclusion: The vessel density of posterior retina was lower in children with T1DM with MDI than in healthy control children and associated with higher hemoglobin A1c. There was a significant difference on vessel density betweenT1DM-MDI and T1DM-CSII, with the similar hemoglobin A1c. This study suggested that optical coherence tomography angiography could be beneficial for the detection of retinal abnormalities in children with early T1DM, and continuous subcutaneous insulin infusion may be a better choice than MDI for children with T1DM to prevent the retinal complication.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Thu, 18 Apr 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 44(5):895-900, May 2024. doi: 10.1097/IAE.0000000000004028";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202405000-00018";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:45;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:106:"https://journals.lww.com/retinajournal/fulltext/2020/09000/ranibizumab_treatment_in_treatment_naive.5.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:249:"Holz, Frank G.; Figueroa, Marta S.; Bandello, Francesco; Yang, Yit; Ohji, Masahito; Dai, Hong; Wykrota, Halina; Sharma, Sanjay; Dunger-Baldauf, Cornelia; Lacey, Sue; Macfadden, Wayne; Mitchell, Paul; on behalf of all the LUMINOUS study investigators";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:135:"RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1850:"<a href="https://journals.lww.com/retinajournal/fulltext/2020/09000/ranibizumab_treatment_in_treatment_naive.5.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202009000-00005.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in treatment-naive patients with neovascular age-related macular degeneration enrolled in LUMINOUS study. Methods: This 5-year, prospective, multicenter, observational study recruited 30,138 adult patients (treatment-naive or previously treated with ranibizumab or other ocular treatments) who were treated according to the local ranibizumab label. Results: Six thousand two hundred and forty-one treatment-naive neovascular age-related macular degeneration patients were recruited. Baseline (BL) demographics were, mean (SD) age 75.0 (10.2) years, 54.9% females, and 66.5% Caucasian. The mean (SD) visual acuity (VA; letters) gain at 1 year was 3.1 (16.51) (n = 3,379; BLVA, 51.9 letters [Snellen: 20/92]) with a mean (SD) of 5.0 (2.7) injections and 8.8 (3.3) monitoring visits. Presented by injection frequencies <3 (n = 537), 3 to 6 (n = 1,924), and >6 (n = 918), visual acuity gains were 1.6 (14.93), 3.3 (16.57), and 3.7 (17.21) letters, respectively. Stratified by BLVA <23 (n = 382), 23 to <39 (n = 559), 39 to <60 (n = 929), 60 to <74 (n = 994), and β₯74 (n = 515), visual acuity change was 12.6 (20.63), 6.7 (17.88), 3.6 (16.41), 0.3 (13.83), and β3.0 (11.82) letters, respectively. The incidence of ocular/nonocular adverse events was 8.2%/12.8% and serious adverse events were 0.9%/7.4%, respectively. Conclusion: These results demonstrate the effectiveness and safety of ranibizumab in treatment-naive neovascular age-related macular degeneration patients.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Tue, 19 Nov 2019 00:00:00 GMT-06:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:74:"RETINA. 40(9):1673-1685, September 2020. doi: 10.1097/IAE.0000000000002670";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202009000-00005";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:46;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:114:"https://journals.lww.com/retinajournal/fulltext/2024/01000/retinal_tectonics_after_macular_pucker_surgery_.14.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:140:"Scarinci, Fabio; Querzoli, Giorgio; Cosimi, Pamela; Ripandelli, Guido; Romano, Mario R.; Cacciamani, Andrea; Munk, Marion R.; Rossi, Tommaso";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:101:"RETINAL TECTONICS AFTER MACULAR PUCKER SURGERY: Thickness Changes and: En Face: Displacement Recovery";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2256:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/01000/retinal_tectonics_after_macular_pucker_surgery_.14.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202401000-00014.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To study visual function, retinal layer thickness changes, and tangential displacement after pars plana vitrectomy for epiretinal membrane. Methods: Retrospective series of patients undergoing pars plana vitrectomy for epiretinal membrane, with 6-month follow-up including best-corrected visual acuity, optical coherence tomography, M-charts, epiretinal membrane grading, and infrared fundus photograph at time 0 (T0, preop) at months 1 (T1), 3 (T3), and 6 (T6) postop (Β±1 week). Retinal layer thickness and tangential (en face) retinal displacement between successive times for the entire retinal surface and the central horizontal and vertical meridian were also measured. En face displacement was calculated as optical flow of consecutive images. Results: Average best-corrected visual acuity improved from 0.28 Β± 0.08 logarithm of Minimum Angle of Resolution at T0 to 0.16 Β± 0.25 at T6 (P = 0.05), best-corrected visual acuity improvement correlated with best corrected visual acuity (BCVA) at T0 (P < 0.001). Vertical metamorphopsia decreased from 1.33Β° Β± 0.70Β° at T0 to 0.82Β° Β± 0.69Β° at T6 (P < 0.05). Foveal thickness reduced from 453 Β± 53 Β΅m at T0 to 359 Β± 31 Β΅m at T6 (P < 0.05) and reduction correlated with best-corrected visual acuity improvement (P < 0.05). Foveal layers decreased (P < 0.05) in all cases. The mean en face deformation was 155.82 Β± 50.17 Β΅m and mostly occurred in the first month: T0-T1 displacement was 83.59 Β± 30.28 Β΅m, T1βT3 was 36.28 Β± 14.45 Β΅m, while T3βT6 was 39.11 Β± 22.79 Β΅m (P < 0.001) on average. Perifoveal and parafoveal deformation correlated with optical coherence tomography foveal thickness reduction at all time intervals (1, 3, and 6 months: P < 0.01). Conclusion: Epiretinal membrane peeling affects all retinal layer thickness and results in new force balance across the entire retina and tangential displacement. Both en face and in-depth changes correlate with visual function.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 01 Jan 2024 00:00:00 GMT-06:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:70:"RETINA. 44(1):102-110, January 2024. doi: 10.1097/IAE.0000000000003928";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202401000-00014";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:47;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:111:"https://journals.lww.com/retinajournal/fulltext/2018/06000/checkpoint_inhibitor_immune_therapy__systemic.1.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:86:"Dalvin, Lauren A.; Shields, Carol L.; Orloff, Marlana; Sato, Takami; Shields, Jerry A.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:6:"Review";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:85:"CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1876:"<a href="https://journals.lww.com/retinajournal/fulltext/2018/06000/checkpoint_inhibitor_immune_therapy__systemic.1.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-201806000-00001.T1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: To review immune checkpoint inhibitor indications and ophthalmic side effects. Methods: A literature review was performed using a PubMed search for publications between 1990 and 2017. Results: Immune checkpoint inhibitors are designed to treat system malignancies by targeting one of three ligands, leading to T-cell activation for attack against malignant cells. These ligands (and targeted drug) include cytotoxic T-lymphocyte antigen-4 (CTLA-4, ipilimumab), programmed death protein 1 (PD-1, pembrolizumab, nivolumab), and programmed death ligand-1 (PD-L1, atezolizumab, avelumab, durvalumab). These medications upregulate the immune system and cause autoimmune-like side effects. Ophthalmic side effects most frequently manifest as uveitis (1%) and dry eye (1β24%). Other side effects include myasthenia gravis (n = 19 reports), inflammatory orbitopathy (n = 11), keratitis (n = 3), cranial nerve palsy (n = 3), optic neuropathy (n = 2), serous retinal detachment (n = 2), extraocular muscle myopathy (n = 1), atypical chorioretinal lesions (n = 1), immune retinopathy (n = 1), and neuroretinitis (n = 1). Most inflammatory side effects are managed with topical or periocular corticosteroids, but advanced cases require systemic corticosteroids and cessation of checkpoint inhibitor therapy. Conclusion: Checkpoint inhibitors enhance the immune system by releasing inhibition on T cells, with risk of autoimmune-like side effects. Ophthalmologists should include immune-related adverse events in their differential when examining cancer patients with new ocular symptoms.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Fri, 01 Jun 2018 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:69:"RETINA. 38(6):1063-1078, June 2018. doi: 10.1097/IAE.0000000000002181";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-201806000-00001";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:48;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:109:"https://journals.lww.com/retinajournal/fulltext/2024/05000/objective_quantification_of_depth_of_field.16.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:116:"Zhang, Xiang; Hu, Hanling; Li, Wenbo; Zhu, Danni; Nie, Zetong; Guo, Haoxin; Wang, Zhaoxiong; Li, Xiaorong; Hu, Bojie";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:147:"OBJECTIVE QUANTIFICATION OF DEPTH-OF-FIELD ADVANTAGE IN 3D SURGICAL VIDEO SYSTEM FOR VITREORETINAL SURGERY: Safety and Efficacy in Macular Diseases";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1569:"<a href="https://journals.lww.com/retinajournal/fulltext/2024/05000/objective_quantification_of_depth_of_field.16.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202405000-00016.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: The objective of this study was to demonstrate, based on objective clinical indicators, the advantages of depth of field provided by the 3D surgical video system compared with the traditional microscope during vitrectomy for treating epiretinal membranes or macular holes. Methods: A total of 38 patients were included in this study and randomly assigned to either the 3D surgical video group or the conventional microscope group. Surgical parameters, such as the focal plane adjustment frequency, membrane peeling time, and number of attempts to peel the membrane, were recorded for each patient. In addition, patients were followed up for 3 months postoperatively. Results: No significant differences were observed in age, sex, operated eyes, or follow-up rates between the groups. The 3D group had significantly lower focal plane adjustment frequency in macular hole surgery and epiretinal membrane surgery. No significant differences were observed in peeling maneuvers, time, or total surgical time. Postoperative follow-up data showed no significant differences. Conclusion: In conclusion, the 3D surgical video system exhibits potential advantages in depth of field. The 3D surgical video system is a safe and effective technology in vitrectomy for macular diseases.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Thu, 18 Apr 2024 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:66:"RETINA. 44(5):878-886, May 2024. doi: 10.1097/IAE.0000000000004027";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202405000-00016";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:49;a:6:{s:4:"data";s:68:" ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:9:{s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:108:"https://journals.lww.com/retinajournal/fulltext/2022/08000/deep_learning_based_prediction_of_outcomes.7.aspx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:71:"Kim, Soo Han; Ahn, Honggi; Yang, Sejung; Soo Kim, Sung; Lee, Jong Hyuck";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:14:"Original Study";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:95:"DEEP LEARNING-BASED PREDICTION OF OUTCOMES FOLLOWING NONCOMPLICATED EPIRETINAL MEMBRANE SURGERY";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:1773:"<a href="https://journals.lww.com/retinajournal/fulltext/2022/08000/deep_learning_based_prediction_of_outcomes.7.aspx"><img src="https://images.journals.lww.com/retinajournal/SmallThumb.00006982-202208000-00007.F1.jpeg" border="0" align ="left" alt="image"/></a>Purpose: We used deep learning to predict the final central foveal thickness (CFT), changes in CFT, final best corrected visual acuity, and best corrected visual acuity changes following noncomplicated idiopathic epiretinal membrane surgery. Methods: Data of patients who underwent noncomplicated epiretinal membrane surgery at Severance Hospital from January 1, 2010, to December 31, 2018, were reviewed. Patient age, sex, hypertension and diabetes statuses, and preoperative optical coherence tomography scans were noted. For image analysis and model development, a pre-trained VGG16 was adopted. The mean absolute error and coefficient of determination (R2) were used to evaluate the model performances. The study involved 688 eyes of 657 patients. Results: For final CFT, the mean absolute error was the lowest in the model that considered only clinical and demographic characteristics; the highest accuracy was achieved by the model that considered all clinical and surgical information. For CFT changes, models utilizing clinical and surgical information showed the best performance. However, our best model failed to predict the final best corrected visual acuity and best corrected visual acuity changes. Conclusion: A deep learning model predicted the final CFT and CFT changes in patients 1 year after epiretinal membrane surgery. Central foveal thickness prediction showed the best results when demographic factors, comorbid diseases, and surgical techniques were considered.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:35:"Mon, 01 Aug 2022 00:00:00 GMT-05:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"citation";a:1:{i:0;a:5:{s:4:"data";s:71:"RETINA. 42(8):1465-1471, August 2022. doi: 10.1097/IAE.0000000000003480";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"copyright";a:1:{i:0;a:5:{s:4:"data";s:43:"(C)2010 Lippincott Williams & Wilkins, Inc.";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:24:"00006982-202208000-00007";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}}}}}}}}}}}}s:4:"type";i:128;s:7:"headers";a:25:{s:4:"date";s:29:"Thu, 23 May 2024 12:21:11 GMT";s:12:"content-type";s:30:"application/xml; charset=utf-8";s:14:"content-length";s:5:"53275";s:10:"connection";s:10:"keep-alive";s:6:"cf-ray";s:20:"8885011ab88aa8ff-MAA";s:15:"cf-cache-status";s:3:"HIT";s:13:"accept-ranges";s:5:"bytes";s:3:"age";s:5:"53293";s:13:"cache-control";s:21:"public, max-age=25200";s:16:"content-encoding";s:4:"gzip";s:7:"expires";s:29:"Fri, 17 May 2024 17:12:32 GMT";s:13:"last-modified";s:29:"Fri, 17 May 2024 10:12:32 GMT";s:25:"strict-transport-security";s:35:"max-age=15552000; includeSubDomains";s:4:"vary";s:15:"Accept-Encoding";s:23:"content-security-policy";s:300:"frame-ancestors 'self' teams.microsoft.com *.teams.microsoft.com *.skype.com *.teams.microsoft.us local.teams.office.com *.powerapps.com *.yammer.com *.officeapps.live.com *.office.com *.stream.azure-test.net *.microsoftstream.com *.dynamics.com *.microsoft.com onedrive.live.com *.onedrive.live.com;";s:11:"ejp-machine";s:5:"WEB01";s:11:"ejp-request";s:36:"86d5e2c1-02a6-4387-8fa8-01d013d21e47";s:10:"request-id";s:36:"6c8329a1-223b-f0c3-d9ba-f51c4ed3b625";s:22:"x-content-type-options";s:7:"nosniff";s:8:"x-ejp-bs";s:1:"1";s:12:"x-ejp-status";s:3:"bot";s:15:"x-frame-options";s:22:"SAMEORIGIN, SAMEORIGIN";s:14:"x-ms-invokeapp";s:18:"1; RequireReadOnly";s:10:"set-cookie";s:416:"__cf_bm=bb6sji9W7mZv.prAjqf.ZglJe.DnqmV65bHtdVygW9U-1716466871-1.0.1.1-EQHwn2494kuPuGm5f6EVd.dtfNNavyFymE4ZRkWyEogaUS1ngms7fcwrF3cnyvktH8pWefjdbFD8tl_Io_IcFXJbMy3zw_ht6DII3jGfIcY; path=/; expires=Thu, 23-May-24 12:51:11 GMT; domain=.lww.com; HttpOnly; Secure; SameSite=None, _cfuvid=6b9c1Os7vFRai1xhrRKE7T5V2ovLF3MGYnTjeAX0kYM-1716466871524-0.0.1.1-604800000; path=/; domain=.lww.com; HttpOnly; Secure; SameSite=None";s:6:"server";s:10:"cloudflare";}s:5:"build";s:14:"20170417072931";}